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11 INTRODUCTION
Many structurally and pharmacologically unrelated drugs are known to bind to melanin,
a complex pigment polymer found in several human tissues (Potts 1964; Solano 2014).
Melanin acts as a natural depot, releasing drugs slowly to surrounding tissues. Binding
has been shown to prolong the terminal elimination half life of drugs in comparative
studies with albino and pigmented animals (Acheampong et al. 1995; Ono et al. 2003).
It also prolongs the action of a drug in the target tissue, reduces the peak concentration
and the toxicity (LeBlanc et al. 1998).
Drug delivery to the posterior part of the eye, where severe eye diseases like diabetic
retinopathy and age-related macular degeneration locate, is challenging (Del Amo and
Urtti 2008). Poor bioavailability in target tissue is a problem in traditional treatment,
with tablets and eye drops. New medicines targeted to the posterior eye segment include
different invasive techniques to administrate drugs or nucleotides in micro- or
nanospheres. Short duration in target tissue and poor patient acceptance are
disadvantages of these techniques. Also long-acting implants are developed, but they
are  still  rarely  used  in  ophthalmic  care.  Therefore  more  safe  and  comfortable  drug
delivery systems for posterior eye diseases are needed.
Melanin is highly concentrated in posterior tissues of the eye: retinal pigment
epithelium (RPE) and melanocytes of the choroid (Prota et al. 1998; Strauss 2005).
Since several drugs are known to bind to melanin, pigment targeted long-acting drug
delivery systems might serve an option in ocular diseases. With this strategy even
systemic drug delivery could be possible. As a setback, drug targeted to melanin of the
eye can potentially distribute to any melanin containing tissue.
In this Master’s thesis, characteristics of melanin and its distribution in humans are
described and compared to different animals. Also melanin binding of drugs in several
tissues is looked through. Distribution kinetics of two different melanin binding drugs
after  intravenous  administration  are  studied  with  pigmented  and  albino  rats  with
SPECT/CT (single photon emission computed tomography/computed tomography)
2imaging method in order to find out if this method can be used in melanin binding
studies. SPECT/CT offers a real-time in vivo study method of radiolabeled drugs with
high  spatial  resolution.  Same  rats  can  be  used  in  all  time  points  and  number  of  study
animals can be reduced. When successful, SPECT/CT imaging can be used in upcoming
studies where aim is to develop melanin targeted drug delivery system to ocular
diseases.
2 MELANIN AND MELANOSOMES
2.1 Eumelanin and Pheomelanin
Melanin is a generic name for a polymorphous group of pigments, which are widely
spread to the nature (Solano 2014). It can be divided into two main subgroups:
eumelanin and pheomelanin. These subgroups vary with their biosynthesis, chemical
structure and functional properties.
Eumelanin is an insoluble black to brown pigment, which acts as a photoprotective
antioxidant (Raper 1926; Ito et al. 2000). It is composed of reduced or oxidized 5,6-
dihydroxyindole (DHI) and 5,6-dihydroxyindole-2-carboxylic acid (DHICA) subunits.
These  subunits  are  linked  to  each  other  via  covalent  C-C  bonds  to  form  a  complex
biopolymer, where some of the indole rings of the subunits are split to pyrrole rings (Ito
2003). Pheomelanin is an alkali-soluble, sulfur-containing yellow to reddish brown
pigment, which is, in contrast to eumelanin, a phototoxic pro-oxidant (Prota 1980;
Wakamatsu et al. 2009). It is composed of benzothiazine and benzothiazole subunits,
which are linked to each other via C-C bonds.
In nature, eumelanin and pheomelanin are mostly formed in mixed melanogenesis,
where the formation of eumelanin follows formation of pheomelanin (Ito and
Wakamatsu 2008). Both pigments are synthesized from the amino acid tyrosine, which
is oxidized by tyrosinase to dopaquinone (DQ), a highly reactive ortho-quinone. When
there are sulfhydryl compounds present, pheomelanin synthesis takes place. Glutathione
3(GSH) or free cysteine is added to DQ to form mainly 5-S-cysteinyldopa and 2-S-
cysteinyldopa or 5-S-glutathionyldopa and 2-S-glutathionyldopa isomers (Prota 1980).
Further oxidation of these thiole adducts leads to benzothiazine and benzothiazole and
formation of pheomelanin via polymerization (Prota 1980; Wakamatsu et al. 2009).
Eumelanin synthesis takes place when all sulfhydryl compounds are used (Ito and
Wakamatsu 2008). DQ undergoes intramolecular addition of the amino group to form
cyclodopa, which is rapidly oxidized through a redox exchange to form dopachrome
and dopa (dihydroxyphenylalanine). Dopachrome spontaneously rearranges to form
DHI and DHICA. In natural eumelanin the most common subunit is DHI. At acidic pH
dopachrome tautomerase (Dct, also termed tyrosinase-related protein-2, Tyrp-2)
catalyzes the tautomerization of dopachrome to DHICA (Aroca et al. 1992; Tsukamoto
et al. 1992). Also the presence of metal cations in the environment raises the amount of
DHICA in eumelanin. Oxidation and polymerization of these subunits lead to
production of eumelanin.
Molecular structure of eumelanin and pheomelanin polymers is challenging to
characterize because of their heterogeneity, insolubility of eumelanin and their nature to
be present as mixtures with each other, lipids, proteins and metals (Ito et al. 2000;
Ghiani et al. 2008). Also subunits of the polymers are difficult to separate because of
the covalent C-C bonds. Nevertheless, Ito and Wakamatsu (2008) have represented
structures of eumelanin and pheomelanin based on their studies of melanin biosynthesis
and degradation (Figures 1(A) and 2(A)). Also Solano (2014) has presented structural
models for eumelanin and pheomelanin (Figures 1(B) and 2(B)). Their views of
pheomelanin structure are very similar, but the (B) eumelanin differs from the (A)
eumelanin by combining possible side products of the polymerization to the structure.
In polymerization part of the eumelanin synthesis, a small amount of oxidized units of
5,6-indolequinone, L-dopa units and carboxylated pyrroles from the environment can be
incorporated to the structure. The C-C bonds can be formed in different positions to the
molecule, e.g. 2, 3, 4 and 7.
4Figure 1. Two possible structures of eumelanin, which consists of 5,6-dihydroxyindole
(DHI) and 5,6-dihydroxyindole-2-carboxylic acid (DHICA) subunits (modified from Ito
and Wakamatsu (2008) and Solano (2014)). (A) Eumelanin represents a view of the
structure from Ito and Wakamatsu (2008) and (B) Eumelanin represents corresponding
from Solano (2014). In polymerization part of the synthesis oxidized units of 5,6-
indolequinone, L-dopa units and carboxylated pyrroles can also be incorporated to the
structure. Arrows describe possible directions for additional subunits.
Figure 2. Two possible structures of pheomelanin, which consists of benzothiazine and
benzothiazole subunits. (A) Pheomelanin represents a view of Ito and Wakamatsu
(2008); (B) Pheomelanin represents a view of Solano (2014). Same substructures are
found in both pheomelanin structures, but their position is different. Arrows describe
possible directions for additional subunits.
52.2 Melanosome
Melanosomes are lipid membrane covered cell organelles, where melanin synthesis and
store occurs (Prota et al. 1998). In humans, melanin synthesis takes place in developing
melanosomes in melanocytes and pigmented epithelial cells. Mature melanosomes can
then be transported to surrounding cells, e.g. keratinocytes of the skin. Some of the
quinone intermediate products of melanin synthesis are highly reactive; therefore
melanosome  shell  protects  the  cells  from  the  toxic  intermediates.  The  shape  of  the
melanosomes varies within the origin tissue and animal from spherical to ovoid and rod-
shaped (Liu et al. 2005a; Liu et al. 2005b; Peles et al. 2009). Also size of the
melanosomes varies within the origin. Distribution of different shaped and sized
melanosomes are described more detailed in chapter 3. Melanin is packed densely in
20-30 nm substructures in single melanosome. In addition to the melanin, melanosomes
contain proteins, enzymes, lipids, and metals.
There  are  several  reviews  of  melanosome development  and  transport,  but  the  focus  in
this  study  is  the  chemical  and  physical  characteristics  of  melanosomes,  as  well  as  the
components in melanosomes, which can affect to the binding properties of the drugs
(Marks and Seabra 2001; Setaluri 2003).
2.2.1 Pigment organization
Melanin  pigment  is  the  main  component  in  a  melanosome.  Its  organization  inside  the
melanosome has been studied lately and a casing model of mixed melanogenesis has
been suggested (Bush et al. 2006; Ito 2006).
As mentioned earlier, eumelanin and pheomelanin are mostly formed in mixed
melanogenesis (Ito and Wakamatsu 2008). Cysteinyldopa formation occurs first, then in
the presence of cysteine, formation of pheomelanin takes place, and finally formation of
eumelanin begins after cysteine molecules are used. Bush et al. (2006) suggested that in
this kind of melanogenesis a pheomelanin core and a eumelanin surface are formed. It
was depicted by Ito (2006), and it is presented in figure 3. Bush and his co-workers used
6particular photoelectron emission microscopy (PEEM) coupled to a free electron laser
(FEL) to analyze ionization threshold of the surface of neuromelanin granules (for
detailed description of neuromelanin, see section 3.5), large pigment aggregates and
small regions within a pigment. The results of all surfaces corresponded to the oxidation
potential of eumelanin, which was earlier detected by Ye and his co-workers (2006)
with human hair eumelanosomes compared to pheomelanosomes. Since neuromelanin
is chemically composed of both pheomelanin and eumelanin, the casing model would
explain the eumelanin surface (Wakamatsu et al. 2003; Ito 2006).
Figure 3. Casing model of mixed melanogenesis (modified from Ito 2006). First,
pheomelanin is produced from cysteine and dopaquinone (DQ), and after there are no
cysteine molecules available, eumelanin synthesis takes place to form a eumelanin
surface on the pheomelanin core. In the granule with eumelanin surface, the side of the
granule is cut away to show the core inside.
Same kind of encapsulation of pheomelanin inside eumelanin core has been found also
from iridal stroma melanosomes of brown and blue-green human eyes (Peles et al.
2009). Also Peles and his co-workers used PEEM-FEL technique to analyze oxidation
potential of the surface of the melanosomes. Because the eumelanin/pheomelanin
concentration ratio varies between 1.3 and 14.8 within different colored irises and the
size of the melanosomes is rather invariable, they considered that the thickness of the
pheomelanin core and the outer eumelanin layer varies based on the color of the iris
(Wakamatsu et al. 2006; Peles et al. 2009). In their model for 30 nm diameter
melanosome substructure, the thickness of the pheomelanin core was 12 nm and
eumelanin layer 9 nm for brown irises, and 23 and 3.6 nm for blue-green irises. Since
the electron escape depth for melanosomes with PEEM-FEL technique is expected to be
7a  few  nanometers,  it  is  possible  with  this  technique  that  in  case  of  a  really  thin  outer
layer of eumelanin also a pheomelanin core near the surface could be detected.
Eumelanin and pheomelanin have different functional characteristics when it comes to
binding metals and chemicals (described in chapter 4) as well as antioxidant properties
(Wakamatsu et al. 2008; Wakamatsu et al. 2009). The more eumelanin is present
compared to pheomelanin, the more antioxidant the pigment is. This further supports
the casing model. Eumelanin surface acts as an antioxidant but with age and continuous
oxidative stress the pro-oxidative pheomelanin core can be exposed, and therefore lead
to increasing oxidative damage of the cells. Based on this model, if a drug binds to the
surface of the melanosome, it binds to eumelanin.
2.2.2 Lipids
Ward and Simon (2006) extracted lipids from ocular melanosomes from RPE,
iris/ciliary body and choroid and analyzed them with liquid chromatography-mass
spectrometry (LC-MS).  There were more than 100 different lipids found in each type of
melanosome. Most of them were located in the membrane, but researchers argued that
they  can  also  be  inside  the  melanosome,  where  they  are  able  to  dissolve  in  extracting
solution by moving through channels in the structure. Removal of the lipids did not
effect to the morphology of the melanosome, which indicates that their role is not
related to the melanosome structure.
The lipid composition of the two uveal melanosomes (iris/ciliary body and choroid) was
similar, but differed significantly from the RPE melanosome lipids (Ward and Simon
2006). Uveal melanosomes consisted mainly of sphingomyelin and other ceramide-
based lipids, which increase structural rigidness of membranes. Glycerophosphoinositol
and glycerophosphoglycerol also found in uveal melanosomes typically regulate protein
binding. Lipids of RPE melanosomes were mostly polyunsaturated fatty acids and
plasmalogen. Polyunsaturated glycerophosphoethanolamines, which were the main lipid
component, are involved in solute transport, folding of membrane proteins and acting as
a protector against reactive oxygen species (Dowhan 1997; Ward and Simon 2006).
8Plasmalogen glycerophosphoethanolamines, which contain fatty vinyl ether in their
structure, can inactivate reactive oxygen species especially when there are metal cations
present (Gorgas et al. 2006; Ward and Simon 2006). This indicates that also lipids can
take part in antioxidant functions in the RPE melanosomes. Melanosomes contained
also glycerophosphoserine and glycerophosphate, which were not found in the uveal
samples.
Drugs have to pass the lipid membrane of melanosomes in order to access melanin (Ings
1984). Therefore lipophilic and small molecules are expected to access melanin through
the  membrane.  Different  lipids  of  uveal  and  RPE  melanosomes  may  affect  to  the
permeability of drugs.
2.2.3 Proteins
Proteomics of melanosomes has been studied with porcine RPE cells and human
melanoma cell line MNT1 in three developmental stages of melanosome maturation
(early stages I and II; and mature stage IV) (Basrur et al. 2002; Azarian et al. 2005; Chi
et al. 2006). 102 proteins were identified from the RPE melanosome. Basrur and his co-
workers found 68 proteins from early melanosomes (developmental stages I-II) of
MNT1 cells whereas Chi and his colleagues found circa 600 proteins from each
developmental stage (I, II and IV).
There are some challenges in melanosome proteomics that explain the difference in the
results to some extend. Proteins can bind covalently to melanin, which makes them
insoluble (Basrur et al. 2002; Azarian et al. 2005; Chi et al. 2006). Melanin, even in
small  amounts,  results  in  a  change  in  electrophoretic  resolution  of  protein,  blocks
antibody epitopes used in Western blotting and degrades LC-MS performance by
binding to chromatographic columns. Basrur et al. did not separate proteins from
melanin,  because  it  is  known  that  there  is  only  a  small  amount  of  it  in  early
melanosomes. Melanosomal preparations of both research groups were also
contaminated by cell organelles, what increases the amount of detected proteins. Both
9groups argued that the contamination percent is low. Protein digestion methods differed
within groups, so careful evaluation and validation of the methods is needed.
Despite the differing number of melanosome proteins, some important proteins were
found in all previously mentioned studies (Basrur et al. 2002; Azarian et al. 2005; Chi et
al. 2006). Melanosomes included proteins of melanogenesis (e.g. Dct), acidification
(vacuolar H+ATPase, also termed V-ATPase), motility, cytoskeleton, proteolytic
enzymes, channels, and transporters. The majority of proteins in RPE and MNT1 cell
melanosome proteome are also found in proteomes of other cell organelles, such as
endoplasmic reticulum, mitochondria, Golgi apparatus, phagosomes, lysosomes,
peroxisomes and nucleus.
Two proteins belonging to ABC (ATP-Binding Cassette) family related to multidrug
resistance were found in RPE melanosome and in mature MNT1 cell melanosome
(Azarian et al. 2005; Chi et al. 2006). ABC subfamily C member 4, also known as
MRP4 (Multidrug Resistance Associate Protein 4) was found from the RPE
melanosome. It acts as an organic anion transporter and has a broad substrate
specificity, including exogenous and endogenous compounds, e.g. antiretroviral drugs,
cyclic nucleotides, eicosanoids and GSH conjugates (Keppler 2011). It can be located
both in luminal and apical sides of the membranes in humans. According to the study of
Azarian et al., one can not say if MRP4 is an efflux or influx transporter in melanosome.
Considering the proteolytic action in melanosomes, it is possible that MRP4 acts as an
influx transporter taking part in degradation process of specific substances. Moreover,
because melanin binds cationic substances, the function of organic anion transporter is
most probably not related to melanin binding (Ings 1984). Organic cation transporters
were not found from the melanosomes.
ABC subfamily F member 1 (ABCF1) was found from mature MNT1 cell melanosome
(Chi et al. 2006). Heimerl and her co-workers found ABCF1 in several other melanoma
cell  lines  as  well  as  normal  human  epidermal  melanocytes  NHEM  P2  and  NHEM  P3
(Heimerl et al. 2007). They studied the proteomics of whole melanocytes, so also
melanosome proteins can be detected. This protein locates typically in ribosomal
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membranes inside the cells, so it can also be a contamination product in Chi and his co-
workers’  study.  It  is  known  that  there  are  no  trans-membrane  domains  in  ABCF1
(Zhang 2007). Therefore, even if it is a member of multidrug resistance associated ABC
family; it can not act as a drug transporter.
2.2.4 Melanosomal pH
Melanosomal pH is an important factor affecting ionization of common group of drugs,
weak asids and bases, and therefore their binding characteristics to melanin.
Melanosomes of the Caucasian skin have acidic pH, whereas pH of melanosomes
isolated from black skin is neutral (Fuller et al. 2001). This corresponds to melanosomal
tyrosinase activity, which is the highest at pH 7.5 and inactive below pH 6.0. There is a
constant melanin production in melanosomes with high tyrosinase activity in black skin,
and none or very little tyrosinase activity in the Caucasian skin. Melanosomal pH is
hypothesized to be regulated either by vacuolar H+ATPase or Na+/H+ exchanger.
Proteomic studies described in previous chapter prove that vacuolar H+ATPase is
present at least in porcine RPE cells and human melanoma cell line MNT1.
Ancans et al. (2001) studied melanosomal pH in 11 human melanocyte cultures (9
Caucasian and 2 black skin types) and in 3 melanoma cell lines. Their results corresponded
to the results of Fuller’s research group (2001). According to these studies, it seems that
melanosomal pH regulates the eumelanin/pheomelanin ratio and the maturation of
melanosomes in melanocytes and melanoma cells. Melanosomal pH varies between
melanosomes of different developmental stages and individuals with different skin color. It
tends to be acidic in mostly inactive Caucasian skin melanosomes and more neutral in
mostly active black skin melanosomes.
There are no studies on the pH of ocular melanosomes in humans. Tyrosinase activity of
the  bovine  RPE cells  is  very  small  and  developing  melanosomes  have  not  been  found
from the adult human RPE, which indicates that the turnover of melanin in the RPE
either  occurs  at  a  very  slow  rate  or  is  completely  absent  (Hu  et  al.  2008).  Thus,
melanosomal pH is expected to be acidic in the RPE. Also proteins related to vacuolar
acidification found from the porcine RPE support this theory.
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3 MELANIN DISTRIBUTION
Melanin has been found in the eye, inner ear, brain, hair and skin, oral cavity, liver,
heart and pulmonary vein of humans (Watts et al. 1981; Barrett and Raja 1997; Peters et
al. 1995; Busam et al. 2001; Fedorow et al. 2005b; Levin et al. 2009). It can also be
located in adipose tissue of obese individuals and melanoma tissues (Kauzman et al.
2004; Randhawa et al. 2009). In other vertebrates there are additional locations, e.g.
venom glands in snakes; testicles, spleen, kidney and peritoneum in amphibians, fish
and reptiles; and muscles in salmons (Dubey and Rowlin 2014). Melanin is also found
from  young  C57BL  mice  spleen  and,  from  endometrium  of  uterus,  muscle  layer  and
serosa of vagina, meninges, perivascular tissue of spinal cord and interstitium of
lacrimal gland of cynomolgus monkey after a toxic exposure (Van der Heijden 1995;
Sato et al. 2012). Distribution and functions of melanin in specific tissues are summed
in figure 4.
If  a  drug  targeted  to  melanin  in  the  posterior  part  of  the  eye  is  administered
systemically, it can potentially distribute to any melanin containing tissue. In this
section characteristics of melanin containing tissues in humans are described. Also
species differences are discussed as well as the effect of aging to melanin in the eyes.
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Figure 4. Melanin distribution and functions in vertebrates (modified from Dubey and
Rowlin 2014). Distribution of melanin in humans is restricted to the eyes, brain, inner
ear, skin, hair, heart, oral cavity, pulmonary vein, liver, adipose tissue and melanoma
tissues. Functions of melanin in these tissues are discussed more detailed in the text.
Note, that melanin in peritoneum, muscles, spleen, kidney and testicles have not been
detected from humans.
3.1 Skin and Hair
Melanocytes, a specific cell type that produces melanin, originate from the neural crest
(Rawles 1947). Human melanocytes of the skin are mostly located in the basal layer of
the epidermis, but also in hair bulbs of epidermis and in dermis (Figure 5) (Busam et al.
2001; Cikhorek et al. 2007). In rodents, melanocytes are mostly found in the hair bulbs
of the epidermis (Colombo et al. 2011). They exist also in the basal layer of epidermis
in  tail,  ears,  nose  and  paws,  and  in  the  dermis  of  the  ear  auricle,  where  the  fur  is  not
present. Melanocytes of hair follicle are larger, more dendritic and produce larger
melanosomes than epidermal melanocytes (Tobin and Paus 2001). Size of the
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melanosomes varies from 0.3 x 0.6 µm in Caucasian epidermis to 0.8 x 1.5 µm in black
skin epidermis. Epidermal melanocytes transfer melanosomes to surrounding
keratinocytes via their elongated dendrites (Tarafder et al. 2014). There is one
melanocyte  for  every  30-40  keratinocytes  in  the  basal  layer  and  one  melanocyte  for
every five keratinocytes in the hair bulb (Tobin and Paus 2001; Tarafder et al. 2014).
Melanosomes are accumulated above the nucleus in keratinocytes. The locations of
melanocytes in the skin and hair are described in figure 5.
Melanocytes and the melanin in the skin and the hair are responsible of many functions
(Riley 1997). Eumelanin absorbs ultraviolet (UV) radiation due to its conjugated
structure, and therefore protects the skin from UV induced deoxyribonucleic acid
(DNA) damage. It also absorbs visible light providing individual skin and hair color.
Melanin can chelate metal cations via its carboxyl and hydroxyl groups, and therefore
bind them into its structure (Sarna 1976; Liu et al 2005b). The metal ion content of dark
and  light  human  hair  can  be  up  to  4  %  and  1.6  %,  respectively,  of  total  melanosome
mass. Eumelanin and pheomelanin bind Mg2+, Ca2+, Fe3+, Cu2+ and Zn2+ with differing
ratios. Eumelanin can bind Ca2+ three times more efficiently than pheomelanin, whereas
pheomelanin binds Mg2+ and Fe3+ more efficiently. This cation binding of hair
melanosomes  has  been  suggested  as  a  trap  for  excess  metals  and  stock  for  cation
homeostasis.  Melanocytes  are  also  involved  in  immune  system  of  the  skin  (Lu  et  al.
2002). They can act as antigen-presenting cells, secrete cytokines and activate cytotoxic
T-lymphocytes against pathogens.
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Figure 5. Melanocytes of the skin and hair are located in A) the epidermal basal layer
and B) the hair bulb (Cikhorek et al. 2013). Melanosomes are transferred to surrounding
keratinocytes giving the color for the uppest layer of epidermis and the hair.
3.2 Inner Ear
Neural crest originating melanocytes of the inner ear are located in the stria vascularis
of the cochlea and the vestibular organ in humans (Peters et al. 1995; Tachibana 1999).
They form intermediate layer of the stria vascularis, a stratified epithelium producing
K+ rich endolymph of the cochlea. Contrary to other extracellular fluids, the endolymph
contains low concentration of Ca2+ and Na+ and a high positive voltage (80 mV), which
is essential to normal hearing. Melanocytes of the stria vascularis include melanosomes
in different developmental stages, which indicate active melanogenesis.
Melanocytes of the vestibular organ exist in the epithelial dark cell area, which forms a
continuous pigmented layer of the vestibular organ (Peters et al. 1995). Also these
melanocytes are present in various developmental stages. Epithelial dark cells take part
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in K+ circulation of the vestibular endolymph. Similar melanin containing structures of
the inner ear are found in humans and pigmented rodents.
In addition to maintaining ion homeostasis in endolymph of cochlea and vestibular
organ, healthy melanocytes are required for development of the inner ear and hearing
(Tachibana 1999). Heavy noise induces production of reactive oxygen species (ROS),
which  can  harm  sensory  cells  of  the  cochlea.  It  has  been  suggested,  that  melanin  can
protect the inner ear from noise-induced damage by acting as a scavenger of ROS.
3.3 Heart and Pulmonary Vein
Neural crest derived melanocytes were found recently from tricuspid and mitral valve,
chordae tendinae, right atrium and the interatrial septum of mouse heart (Mjaatvedt et
al. 2005). Brit and Kos (2008) confirmed these results and explored the migration of
premelanocytes (also called melanoblasts) to the heart with mouse embryo. They
described how wild type mouse premelanocytes migrate to atrioventricular endocardial
cushions, and evolve to melanocytes in the atrioventricular valves in mature mice.
Researchers also found out that there are no melanocytes in the hearts of frog or
zebrafish, whereas in quail there are. They suggested that pigmentation of the heart is
characteristic to species with four-chambered hearts.
Levin and his co-workers (2009) studied melanocytes of mouse and human hearts. In
addition to previous results, they found melanocytes from left atrium, aortic valve,
pulmonary valve and pulmonary vein of the mouse hearts. In human hearts,
melanocyte-like cells expressing Dct were localized in pulmonary vein, atrium,
coronary sinus, and atrioventricular annulus. Although the cells expressed Dct, the
pigment was not evident in the cells. The research group argued that dysfunction of
these cells located in the atrium or pulmonary vein is related to atrial arrhythmias.
Mutagenic mice lacking Dct did not develop atrial arrhythmias whereas wild type mice
expressing Dct did.
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Melanin of mouse heart is related to the stiffness of the tricuspid valve leaflet (Balani et
al. 2009). Stiffness of the leaflet varies with the amount of pigmentation with positive
correlation.  Levin  et  al.  (2009)  proposed  buffering  of  Ca2+ and  binding  of  ROS  as
possible functions of heart melanin. These functions are not studied with human hearts,
although they are connected to functions of melanin (Riley 1997; Bush and Simon
2007). Despite recent studies related to pigmentation of the heart, degree of melanin in
human melanocytes-like cells is still unknown.
3.4 Eyes
Pigmented cells of the eye develop from two different origins (Hu et al. 2008; Durairaj
et al. 2012).  Melanocytes derived from the neural crest are located in the uveal tract, a
highly vascularized layer between sclera and retina. The uveal tract consists of iris,
ciliary  body and  choroid.  Pigment  has  also  been  detected  in  the  sclera  (Durairaj  et  al.
2012). Pigment epithelia cells (RPE, iris pigment epithelium (IPE) and ciliary pigment
epithelium) are derived from the neural ectoderm together with photoreceptors of the
neural  retina  (Prota  et  al.  1998;  Strauss  2005).  Localization  of  the  pigment  in  the  eye
and the structure of the RPE are depicted in figure 6. Structure of the RPE is discussed
more detailed in chapter 3.4.2.
Figure 6. Localization of the pigment in the eye and the structure of the retinal pigment
epithelium (RPE) (modified from Rózanowska 2011 and Strauss 2005). A) Melanin
(depicted in dark brown color) is located in RPE and uveal tract, which consists of iris,
ciliary body and choroid. B) RPE cells are attached to Bruch’s membrane between
choroid and neural retina. They are fixed together with tight junctions. Several
melanosomes are present in cytoplasm.
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3.4.1 Uveal Melanocytes
Uveal melanocytes include melanocytes of iris, ciliary body and choroid (Prota et al.
1998; Wakamatsu et al. 2009). They are located in the stroma of the tissues. Uveal
melanocytes share a common origin with other melanocytes of the body.
Prota et al. (1998) and Wakamatsu et al. (2008) studied the melanin content of the iris
from different colored human eyes.  According to their  results,  the amount and ratio of
eumelanin and pheomelanin in iris melanocytes define the color of the eye. In brown
eyes, both pigments were detected in highest quantity (eumelanin 25.3 µg /
pheomelanin 6.9 µg/iris) (Prota et al. 1998). Less pigment were found in green-brown
(5.6/1.5 µg/iris), green (2.2/2.5 µg/iris) and blue-green (17.8/0.4 µg/iris) irises, whereas
pigment in the blue iris was almost absent (eumelanin below the detection
limit/pheomelanin 0.03 µg/iris). As mentioned earlier in chapter 2.2.1, melanosomes of
the iris have an outer surface of eumelanin and a core of pheomelanin. Melanosomes of
dark brown irises are larger and more numerous compared to light colored irises (Eagle
1988). Since light color of the iris is a risk factor for uveal melanoma, it is assumed that
melanin of the iris protects the uveal cells from DNA damage by absorbing UV
radiation (Weis et al. 2006).
Wakamatsu et al. (2008) compared the amount of pheomelanin, eumelanin and total
melanin as well as eumelanin/pheomelanin ratio of melanocytes from iris and choroid.
No significant differences were found between these cells. According to this study, the
pigmentation of choroidal melanocytes is related to eye color. Also skin color has been
connected to total melanin quantity in choroid (Weiter et al. 1986). Black skin color
indicates high melanin content in choroid whereas light skin color indicates low content.
Greater concentration of melanin is found from the outer choroid half than from the
inner choroid half. Function of choroidal melanin is unclear, but it has been suggested
to protect the choroid from ROS of the capillary circulation (Hu et al. 2008).  Neither
choroidal nor ciliary body melanocytes are exposed to direct sunlight, so it is unlikely
that they have a role in UV protection.
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3.4.2 Pigmented Epithelial Cells
Pigmented epithelial cells include RPE, IPE and ciliary pigment epithelium (Prota et al.
1998; Strauss 2005). They differ from melanocytes by several factors. In addition to
different embryological origin, RPE cells have a unique lipid content, which was
described in the chapter 2.2.2 (Ward and Simon 2006). The color of the skin or eyes do
not effect on the quantity of melanin in the RPE or IPE, which are highly pigmented and
consist mainly of eumelanin (Weiter et al. 1986; Prota et al. 1998; Wakamatsu et al.
2008). Melanin content of the IPE is similar despite the color of the eyes, so it has been
argued that IPE cells have no role in colorization of the iris.
Pigment  formation  in  the  developing  RPE cells  begins  in  the  fourth  week  of  gestation
(Rózanowska 2011). Melanin synthesis within the RPE melanosomes continues until
two years of age, but whether it occurs afterwards is not known. As described earlier in
chapter 2.2.4, it is believed that melanin turnover in adult RPE is absent or occurs at
very slow rate (Hu et al. 2008).
RPE cells form a monolayer between neural retina and the choroidal capillary system
(Figure 6B) (Strauss 2005). Basolateral side of the cells is attached to Bruch’s
membrane, whereas long microvilli of the apical side reach to the neural retina. RPE
forms a blood-retina-barrier with its tight junctions together with non-fenestrated
endothelial cells of choroid capillaries. Melanosomes are localized on the apical side of
the cell, whereas lipofuscins, membrane-bound organelles containing lipids,
incompletely digested photoreceptor segments and vitamin A derivatives, are located on
the basolateral side (Weiter et al. 1986; Kennedy et al. 1995). The concentration of
lipofuscin  increases  rapidly  after  age  50  whereas  concentration  of  melanin  in  the  RPE
has reported to decrease with age and gradually incorporate into lipofuscin forming
melanolipofuscin granules.
Since UV radiation can pass through the iris and neural retina to reach the RPE, melanin
of the RPE has a major role in absorbing the radiation and protecting surrounding cells
from UV induced DNA damage (Hu et al. 2008). Therefore this photo-protective
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property of melanin can prevent or delay development of age-related macular
degeneration and uveal melanoma. Absorbing also prevents scattering and reflection of
light in the fundus, which is important for the vision. Melanin in the RPE can also bind
ROS, metals and chemical substances.
3.5 Central Nervous System
The pigment in the central nervous system is termed neuromelanin. It is produced in the
most of the dopaminergic neurons of substantia nigra and noradrenergic neurons of
locus coaruleus (Fedorow et al. 2005b). It has also been detected from medulla
oblongata, hypothalamus and cerebellum near the fourth ventricle, but not in visible
amounts. Localization of the neuromelanin in the central nervous system is depicted in
figure 7. Pigmentation of substantia nigra was not found from mice, rats or sheep,
whereas there was visible amount of pigment in baboon substantia nigra neurons
(Double et al. 2011). It has been suggested that neuromelanin exists only in primates;
however there are no extensive studies of the neuromelanin in primates to confirm it.
Neuromelanin formation in the dopaminergic neurons begins at three years of age
(Fedorow et al. 2005c). Pigment granules grow and become more numerous until 20
years  of  age,  when  almost  half  of  the  cytoplasm  is  occupied  by  them.  Melanin
formation continues and the amount of the pigment increases with age, developing
denser melanin granules. These amorphously shaped, 0.5 to 2.5 µm sized granules are
localized on the opposite side of the cell from the nucleus (Double et al. 2008).
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Figure 7. Localization of the pigment in human central nervous system (modified from
Fedorow et al. 2005b). Neuromelanin is localized in A) substantia nigra and B) locus
coeruleus in the highest concentrations in the brain. It has also been detected from C)
hypothalamus, D) cerebellum near the fourth ventricle and E) medulla oblongata, but
not in quantities visible to human eye.
Chemical structure and synthesis of neuromelanin differs from the mixed melanin
produced in melanocytes (Double et al. 2008). It is believed to be formed mainly from
pheomelanin and eumelanin, because it consists of DHI and benzothiazine units
(Wakamatsu et al. 2003). In contrast to mixed melanin in melanocytes, also dopamine,
cysteinyldopamine and dopa are incorporated to the structure of neuromelanin produced
in dopaminergic neurons. It is assumed that in noradrenergic neurons norepinephrine is
a common unit of neuromelanin structure (Double et al. 2011). Sulzer and his co-
workers (2000) suggested that neuromelanin synthesis in dopaminergic neurons takes
place when dopamine and dopa accumulate, and it is catalyzed by iron instead of
tyrosinase. According to their in vitro study, neuromelanin synthesis takes place in
autophagic organelles surrounded by a double membrane. There are no in vivo studies
which would clarify this membrane due to difficulties in preserving human post mortem
samples, and it is also argued that neuromelanin is present in the cytoplasm (Fedorow et
al. 2005b). Due to these differences, neuromelanin granules are clearly separated from
melanosomes of the periphery in the literature.
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There is significant amount of lipids incorporated to the neuromelanin structure
(Fedorow et al. 2005a). 30 % of the neuromelanin mass are lipids, where the main lipid
component  is  dolichol.  Fedorow  et  al.  argued  that  it  may  have  antioxidant  and
membrane stabilizing properties, but this is not clarified with neuromelanin. Other
detected lipids include ubiquinone-10, α-tocopherol and cholesterol. Membrane related
phospholipids have not been detected from neuromelanin. Tribl et al. (2006) studied
proteins incorporated to neuromelanin granules. They found 72 proteins in total, which
had functions related to organelle acidification and mobility as well as digestive
enzymes. Acidification related vacuolar H+ATPase locates to organelle membranes,
which indicates a surrounding membrane for neuromelanin granules.
There are several metal cations incorporated to the neuromelanin structure (Bohic et al.
2008). Fe3+ is  present in the highest  amount,  but also Se2+, Ca2+, Cu2+, Mn2+ and Zn2+
are found from neuromelanin granules of brains with different age. It is widely accepted
that melanin in substantia nigra and locus coeruleus act as an intracellular reservoir for
important  cations,  such  as  Ca2+ and  Cu2+, taking part in their homeostasis. Other
important functions of neuromelanin include binding and inactivating potentially toxic
exogenous substances, ROS and metabolic products, e.g. highly oxidative quinones
(Double et al. 2008).
3.6 Other Pigment Containing Tissues
In addition to previously described distribution of melanin, Watts et al. (1981) detected
a  small  amount  of  melanin  also  from  the  liver  of  healthy  human,  whereas  kidneys
lacked it. Sato et al. (2012) recently published histology pictures of spontaneous lesions
of several tissues from toxicity studies with cynomolgus monkeys. They found brown
and black pigment from Kuppfer cells of the liver and red pulp of the spleen.
Researchers identified brown pigment as hemosiderin, but the black pigment remained
unknown. Based on unpublished data, the group argued that the pigment is not melanin
or lipofuscin. However, they identified melanin from the endometrium of uterus, muscle
layer and serosa of vagina, meninges, perivascular tissue of spinal cord and interstitium
of lacrimal gland. Toxic exposure related to pigment formation was not identified in the
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article. Van der Heijden and his co-workers (1995) found melanin from 14 spleens of 60
young C57BL mice. Researchers localized most of the pigment in melanocytes, whereas
some of it was in macrophages. They were not able to explain the functions of melanin
in individual young spleens.
Melanin has been identified from melanocytes of buccal mucosa and epidermal
Langerhans cells of healthy oral cavity in humans (Barrett and Raja 1997). Variation in
the amount of pigment between individuals corresponds to skin color (Feller et al.
2014). Pigmented lesions in oral cavity can be also induced by several abnormal
conditions, which include smoking, long-term inflammatory mucosal diseases and
pigmentation induced by drugs or other chemicals, e.g. chloroquine, minocycline and
nicotine (Kauzman et al. 2004; Yerger and Malone 2006). Function of the pigmentation
is most probably related to protection the cells from ROS and potentially toxic
chemicals, yet it is unknown why these drugs stimulate only melanocytes in the oral
cavity.
Randhawa et al. (2009) identified first time melanin from adipocytes of morbidly obese
human adipose tissue. They found tyrosinase activity and melanogenesis related genes
from adipose tissue indicating that adipocytes are able to melanogenesis. Furthermore,
adipocytes expressed also melanocortin receptor, which triggers melanogenesis in
melanocytes. Researchers suggested that function of melanin is to bind ROS and
therefore inhibit inflammation in adipose tissue.
Distribution of melanin has been studied with several animals, and this literature review
does not cover them all. It is possible that melanin distribution in humans is wider than
we yet know. Melanocytes can express only small amount of pigment, which is possibly
the case with human heart and certain locations in the brains (Fedorow et al. 2005b;
Levin et al. 2009). Melanogenesis can also be activated in several tissues (e.g. oral
cavity, adipose tissue) after constant exposure to inflammatory agents (Kauzman et al.
2004; Randhawa et al. 2009). Therefore the distribution and amount of eumelanin and
pheomelanin in humans vary between individuals not only with their age and race, but
also with their exposure to inflammatory agents.
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4 MELANIN BINDING DRUGS
As described in previous chapters, one characteristic property of melanin is its ability to
bind a wide range of chemicals, including drugs from different therapeutic areas (Potts
1964; Ings 1984). Drug accumulates to melanin, where it dissociates slowly to
surroundings. Thus, melanin binding alters distribution and elimination kinetics of
drugs by reducing peak concentration in the melanin containing tissue and prolonging
the effect of the drug (Leblanc et al. 1998). This way it can protect the tissue from
possible toxic effects. Binding has been also related to undesirable side effects, such as
ocular toxicity, ototoxicity, skin toxicity and extrapyramidal disorders, although both
Ings (1984) and Leblanc et al. (1998) argued that there are several melanin binding
drugs that cause no toxicity. Therefore toxicity is most probably related to the properties
of the drug rather than to the melanin binding property (Leblanc et al. 1998).
Characteristics of melanin binding are summed and different distribution profiles are
described in this chapter.
4.1 Characteristics of the Melanin Binding
Basic and lipophilic drugs are known to bind to melanin (Ings 1984). Lipophilic drugs
can pass membranes and therefore access into the melanosome. Basic drugs can bind
with electrostatic forces to polyanionic eumelanin structure. There are several functional
groups in eumelanin, which can potentially react with drugs (Riley 1997). Quinone
units of DHI and DHICA can act as electron donors and acceptors. Delocalized
electrons of semiquinones can act as free radical scavengers but also bind drugs by
sharing electrons with them. Carboxyl and hydroxyl groups can bind drugs and chelate
metal cations (Sarna 1976). Aromatic groups can bind chemicals with hydrophobic
forces, and also van der Waals forces take part in binding (Ings 1984). Binding is most
often reversible, and the rate of dissociation depends on the type of the chemical bond
between drug and melanin.
Anti-malarial drugs chloroquine and quinine as well as antipsychotic drug
chlorpromazine are known to bind tightly to melanin (Potts 1964). Chloroquine can
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even retain in the pigment for over 48 weeks (Ono et al. 2003). As some examples,
melanin binding drugs also include β-blockers such as nadolol, betaxolol and
metoprolol; β-agonist salbutamol; antipsychotics such as thioridazine; narcotics like
cocaine and amphetamine; and antibacterial drugs including fluoroquinolone backbone
such as norfloxacin and ciprofloxacin (Potts 1964; Howells et al. 1994; Fukuda et al.
2000; Borges et al. 2003; Kadam et al. 2011). Characteristics of a set of melanin
binding drugs are collected in table 1. It demonstrates that even though lipophilicity is
related to melanin binding, it is not an obligatory feature.
Most of the in vitro melanin binding studies are done with eumelanin rich pigment.
Different sources of melanin for in vitro studies include e.g. human, rabbit, porcine or
bovine eyes, Sepia melanin and synthetic melanin (Kaliszan et al. 1993; Bridelli et al.
2005; Pitkänen et al. 2007; Kadam et al. 2011). Sepia melanin from ink of the cuttlefish
consists of DHICA-rich eumelanin (Pezzella et al. 1997). Natural sources contain both
eumelanin and pheomelanin with differing ratios, as well as proteins, lipids and metal
cations incorporated to the structure (Ito et al. 2000; Kadam et al. 2011). Synthetic
melanin is most commonly formed from dopa or dopamine and DHI units due to simple
synthesis methods (Solano 2014). Therefore its structure has common features with
eumelanin, even though there are no proteins, lipids or metals present in it. Pitkänen et
al. (2007) found several differences between melanin separated from bovine RPE-
choroid and synthetic melanin. Melanin granules were different in their size and shape,
and the surface area of synthetic melanin was two times larger than bovine RPE-choroid
melanin. Synthetic melanin also aggregated markedly during 4 h incubation, whereas
choroid-RPE melanin did not. Synthetic melanin bound more drug than RPE-choroid
melanin due to bigger surface area. According to this, researchers suggested that the
results with melanin separated from natural sources are more reliable than the ones with
synthetic melanin.
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Table 1. Characteristics of a set of melanin binding drugs. Mw = molecular weight; pKa
= logarithm of acid dissociation constant; logP = octanol-water partition coefficient.
Drug Molecular structure
Mw
(g/mol)a
pKa
(acid/base) logPa
Reference for
binding
Antimalarial agents
Chloroquine 319.87
10.8 (base)
8.4 (acid)b 4.6 Potts 1964
Antipsychotics
Thioridazine 370.57 9.5 (base)a  5.9 Potts 1964
Chlorpromazine 318.86 9.3 (base)a 5.2 Potts 1964
β-agonists and β-blockers
Salbutamol 239.31
9.2 (base)
10.7 (acid)a 0.3 Howells et al. 1994
Nadolol 309.40
9.7 (base)
13.9 (acid)a 0.7
Kadam and Kompella
2010
Narcotics
Cocaine 303.35 8.6 (base)a  2.3 Borges et al. 2003
Amphetamine 135.21 9.9 (base)a 1.8 Borges et al. 2003
Antibacterial agents
Norfloxacin 319.33
8.5 (base)
6.3 (acid)a -1.0 Fukuda et al. 2004
Ciprofloxacin 331.34
8.5 (base)
6.1 (acid)a -1.1 Fukuda et al. 2004
a (PubChem 2014) b(Sigma-Aldrich 2014)
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Also synthetic pheomelanin binds drugs, although the binding is less efficient than the
one with eumelanin (Mårs and Larsson 1999). There are also differences in metal cation
binding with these two pigments (Liu et al 2005b). Eumelanin can bind Ca2+ more
efficiently than pheomelanin, whereas pheomelanin binds Mg2+ and Fe3+ more
efficiently. Drug binding properties of pheomelanin are related to electrostatic forces
(Mårs and Larsson 1999). Binding can occur via hydroxyl and carboxyl groups as well
as aromatic and aliphatic amines.
According to the casing model described in chapter 2.2.1, the surface of the natural
melanin formed in mixed melanogenesis consists only of eumelanin, and the thickness
of  the  surface  varies  between individuals  depending  on  the  amounts  of  eumelanin  and
pheomelanin in the melanosome. This kind of casing has been found from neuromelanin
and melanosomes of iridal stroma (Bush et al. 2006; Peles et al. 2009). Thus, one can
hypothesize that drug binding to melanin surface is equal to binding to eumelanin
structure.
4.2 Drug Distribution to Melanin in Different Tissues
Drug accumulation to melanin in different tissues has been depicted in several articles
(Ings 1984; Hamanaka et al. 1990; Barr-Hamilton et al. 1991; Zemel et al. 1995; Gygi
et al. 1996; Slawson 1998; Glas et al. 2007; Vulic et al. 2011). These include
accumulation in the cochlea of the ear, skin and hair, substantia nigra of the brain as
well as the uveal tract and the RPE of the eyes. These represent the tissues where
melanin content is the highest in normal conditions in humans.
Accumulation of drugs to skin and hair pigment has been connected to e.g. cocaine,
amphetamine, salbutamol, phencyclidine and fluoroquinolone antibiotics including
sparfloxacin, ciprofloxacin and norfloxacin. Fluoroquinolone antibiotics induce
phototoxicity by accumulating in human skin pigment (Hamanaka et al. 1990). The
mechanism is yet unknown, although authors suggest that the high concentration of the
drug in the skin causes the toxicity. Gygi et al. (1996) demonstrated codeine
accumulation to the fur after intraperitoneal administration in three rat strains: Long-
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Evans (LE, black and white hairs), Dark Agouti (DA, brown hair) and Sprague-Dawley
(SD, white non-pigmented hair). 2 weeks after the beginning of the study, the fur was
collected and analyzed. Accumulation to the fur rose with the color so that the biggest
amount was found in LE black hair (111.93 ± 18.69 ng/mg) then DA hair (5.99 ± 1.24)
and finally in SD hair (0.98 ± 0.10). Similar results were obtained 2 weeks after
intraperitoneal administration of phencyclidine, which accumulated in the highest
amount in LE black hair (21.20 ± 1.40 ng/mg), then in DA hair (12.25 ± 1.24) and SD
hair (0.46 ± 0.13) (Slawson et al. 1998). Researchers also determined the content of
eumelanin and pheomelanin in the fur. In the black hair of LE rat, eumelanin
concentration was 17.56 ± 0.61 µg/mg (mean ± standard error). Pheomelanin was not
found from the fur of LE rat. From the hair of DA rat, eumelanin and pheomelanin were
detected in concentrations 20.50 ± 1.58 µg/mg and 0.09 ± 0.00 µg/mg. Neither
eumelanin nor pheomelanin were found from the fur of SD rat. Although eumelanin
concentration  was  found to  be  the  highest  in  DA rat,  the  detected  amount  of  the  drug
was the highest in the black hair of LE rat. This can be due to many reasons. The fur can
grow and cleave off at different rates between races during the study period or it can be
contaminated of the drug excreted in feces or urine in the cage. Also the metabolism of
the drug can vary dramatically between the strains. Vulic et al. (2011) found salbutamol
and clenbuterol accumulation in pigmented and albino mice fur in ratios 1:1.4 and 1:2-
4, respectively. According to these studies, drug accumulates to the pigmented fur in
higher quantity than in albino fur. In addition to the amount of melanin in the fur, also
several strain differences can affect to the results.
Comparative studies of drug distribution in pigmented and albino animals have been
conducted with whole-body autoradiography (WBA) method (Kasuya et al. 1975; Ono
et al. 2003). Kasuya and his co-workers (1975) gave intravenous injection of 14C-
chloroquine  to  pigmented  ACI  and  albino  SD male  rats.  Rats  were  euthanized  at  time
points 24 hours and 1 month after drug administration, and radioactivity of the rat
sections were measured. Results of the ACI rat are seen in figure 8. At the time point 24
hours, there are traces of radioactivity in liver, intestine, hair follicles, Harder’s gland
and uveal tract of the eye, but at the time point 1 month, only uveal tract and some
traces in hairs are seen. Accumulation of the drug in the skin or the uveal tract was not
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seen in the albino rat. Ono et al. (2003) compared absorption, metabolism and
distribution of per orally administered 14C-chloroquine in pigmented Brown Norway
(BN) and albino SD male rats. They made WBA pictures from time points 4 weeks, 24
weeks and 48 weeks after administration. In BN rats, accumulation in testis and the
uveal tract of the eye was seen, although at the time point 48 weeks, there was very
small amount left in the testis. A significant amount of radioactivity was still seen in the
uveal tract at the time point 48 weeks. In the albino rats no radioactivity was seen
except for the testis at weeks 4 and 24. There was no radioactivity left at the time point
48 weeks. Researchers suggest that this long-standing binding in the eyes is due to slow
turnover of melanin in the RPE. They argued that the binding of chloroquine is
reversible, because the concentration in the eyes decreased slowly with time. Also 14C-
myosmine has been shown to bind in uveal tract 24 h after intravenous administration to
pigmented LE rat in WBA study (Glas et al. 2007).
Figure 8. Whole-body autoradiography figures of A) 24 hours and B) 4 weeks after
intravenously administered 14C-chloroquine to pigmented ACI rat (Kasuya et al. 1975).
Drug distribution to the eyes has been studied also with topical, transscleral and
intravitreous administration to pigmented and albino animals (Acheampong et al. 1995;
Zemel et al. 1995; Cheruvu et al. 2008). Ocular tissues were isolated from the animals
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and analyzed  either  via  histology  or  biochemical  analysis.  The  amount  of  free  drug  in
the target tissues was smaller for pigmented than albino animals (Acheampong et al.
1995; Cheruvu et al. 2008). Reduced ocular toxicity for pigmented animals compared to
albino animals was reported with gentamicin and brimonidine (Acheampong et al.
1995; Zemel et al. 1995).
As described in chapter 3.5, it has been suggested that neuromelanin exists only in the
brains of primates. Thus, drug distribution to neuromelanin can not be studied with
rodents or other commonly used laboratory animals. 3H-chlorpromazine, 3H-haloperidol
and 14C-imipramine has been shown to accumulate in melanin containing areas of
human brain (Salazar et al. 1978). These drugs also cause extrapyramidal disorders,
which relate to the location of the melanin in substantia nigra. However, more studies
are needed about drug distribution to neuromelanin.
5 AIM OF THE STUDY
Main objective for the exploratory part of this Master’s thesis was to determine first
time ever if melanin binding can be studied in vivo with SPECT/CT imaging method.
To conclude this, two different melanin binding drugs were chosen and an imaging
protocol was developed for this purpose. Chosen drugs were labeled with iodine and
radioactive iodine (123I). Melanin binding of non-labeled and I-labeled drugs was
defined in vitro to confirm the binding and to find out if labeling affects to the binding.
Distribution kinetics of 123I labeled melanin binding drugs was studied in vivo with
SPECT/CT, and results of pigmented and albino rats were compared.
30
6 MATERIALS AND METHODS
6.1 Study Drugs and Labeling
Study drugs were chosen according to three criteria: labeling possibility, different
distribution profiles and optimal elimination profiles. Anti-malarial agent chloroquine
was chosen as the first melanin binding drug (Potts 1964). Since it is very lipophilic
molecule, it is expected to distribute in tissues and access to the RPE through blood-
retina-barrier. It is known to bind tightly to melanin and retain in the pigment for even a
year (Ings 1984). In humans, chloroquine is metabolized to desethylchloroquine,
bisdesethylchloroquine and 4-amino-7-chloroquine, the first being the main metabolite
(MicroMedex 2014). Half of the drug is excreted unchanged via kidneys and one
quarter is excreted as desethylchloroquine. Non-selective β-blocker nadolol was chosen
as the second melanin binding drug (Kadam and Kompella 2010). As a hydrophilic
drug, it was expected to distribute mainly in the water space of the body (i.e. blood).
Therefore it was assumed to bind in the melanin of the melanocytes of the choroid,
whereas it can not access the RPE. Nadolol is excreted unchanged via kidneys in
humans (MicroMedex 2014). Selective β2-agonist salbutamol was chosen as a non-
binding reference, although it was changed later to salicylic acid due to contradictory
data of melanin binding properties of salbutamol (Sauer and Anderson 1994; Howells et
al. 1994). Characteristics of the study drugs are collected to table 2.
Table 2. Characteristics of study drugs. Mw = molecular weight; pKa = logarithm of
acid dissociation constant; logP = octanol-water partition coefficient; t½ = half-life.
Drug Binding
Expected
distribution
Mw
(g/mol)a logPa pKab t½
Chloroquine Positive d tissues 319.87 4.6 10.1 (base)
46.6 h (albino mouse)g
70-120 h (human)c
Nadolol Positive e blood 309.40 0.7
9.7 (base)
13.9 (acid) 20-24 h (human)c
Salbutamol
Negative f/
Positive h blood 239.31 0.3
9.4 (base)
10.1 (acid) 4.6-6 h (human)c
Salicylic acid Negative d blood 138.1 2.3 3.0 (acid) 42 min (human)c
a(PubChem 2014); b(DrugBank 2014); c(MicroMedex 2014); d(Potts 1964); e(Kadam and Kompella, 2010);
f(Sauer and Anderson 1994); g(Moore et al. 2011) h(Howells et al. 1994)
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Chloroquine diphosphate salt, nadolol and salicylic acid were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Salbutamol sulfate was provided by Orion Pharma
(Finland). Drugs were labeled with iodine (127I, presented later as I) and radioactive
iodine (123I, half-life 13 h). 123I was chosen as a radioactive label for SPECT/CT studies,
because it causes a minimal possible change in the chemical structure of chosen
compounds and therefore does not prevent permeation through physiological
membranes, e.g. blood-retina-barrier.
6.1.1 Iodination of Chloroquine, Nadolol and Salicylic Acid
All the chemicals used in labeling were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Na123I was purchased from MAP Medical Technologies Oy (Finland) and all the
buffers for labeling were prepared in situ.
Chloroquine was iodinated with iodosuccinimide. 515 mg (1 mmol) of chloroquine
diphosphate salt was dissolved in 2 ml of 90% sulfuric acid. While stirring, 250 mg (1.1
mmol) of iodosuccinimide in portions of 50 mg was added within 20 min. After all
iodosuccinimide was added, the reaction mixture was kept stirring at room temperature
for 30 min. The reaction mixture was poured on ice and the pH was adjusted to 12.5
with diluted sodium hydroxide. The target compound was extracted with
dichloromethane and washed with brine. Finally, it was purified with thin layer
chromatography (TLC, Kisselgel 60254, Merck,  Germany)  on  silica  gel  (MeOH/Et3N =
40/1). The most pure fractions of TLC were evaporated and dried to give 220 mg of
slightly yellow oil. The reaction of the iodination is depicted in figure 9. The structure
of the I-chloroquine was confirmed by H+ nuclear magnetic resonance (HNMR), which
is presented in figure 1 in appendix 1.
Nadolol was iodinated with potassium iodide (KI). 154 mg (0.5 mmol) of nadolol and
83 mg (0.5 mmol) of KI were dissolved in 10 ml of methanol/water (Milli-Q®) (2/1).
0.2 ml of concentrated hydrochloric acid was added and the reaction was started by
addition of 57 mg (0.25 mmol) of periodic acid. The reaction mixture was refluxed for 3
hours.  The  reaction  was  quenched  by  addition  of  1ml  of  10  %  sodium  thiosulfate
32
solution. The target compound was isolated by semi-preparative high-performance
liquid chromatography (HPLC, Hewlett Packard 1050, Colorado, USA). Settings of the
HPLC run are presented in appendix 2. The structure of I-nadolol was confirmed by
HNMR, which is presented in figure 2 in appendix 1. The reaction of iodination is
depicted in figure 10.
Figure 9. Iodination of chloroquine. Ortho-I-chloroquine is formed in the reaction.
Reaction is provided by Maxim Antopolsky.
Figure 10. Iodination of nadolol. Ortho-I-nadolol is formed in the reaction. Reaction is
provided by Maxim Antopolsky.
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Salicylic acid was iodinated with KI. 70 mg of salicylic acid (0.5 mmol) and 83 mg of
KI (0.5 mmol) were dissolved in 5 ml of water. 1 ml of concentrated hydrochloric acid
was added and the reaction was started by addition of 114 mg (0.5 mmol) of periodic
acid. The reaction mixture was refluxed for 3 hours, and quenched by addition of 1 ml
of 10% sodium thiosulfate solution. The target compound was isolated by semi-
preparative HPLC (settings presented in appendix 2). The reaction of the iodination is
depicted in figure 11. The structure of 3,5-I2-salicylic acid was confirmed by HNMR,
which is presented in figure 3 in appendix 1.
.
Figure 11. Iodination of salicylic acid. 3,5-I2-salicylic acid is formed in the reaction.
Reaction is provided by Maxim Antopolsky.
6.1.2 Radiolabeling of Chloroquine and Nadolol with 123I
Chloroquine was radiolabeled with 123I in a following manner. To the 0.2 ml of 0.5 M
sodium dihydrophosphate buffer (pH 6.0) 0.1 ml of chloroquine diphosphate solution
(153 mg/ml) was added. 0.02 ml of KI solution (1.25 mg/ml) and 0.8 ml of Na123I
solution (420 MBq) were added to the reaction mixture. The reaction was started by
addition of 0.02 ml of chloramine T solution (10 mg/ml).
After  15  min  of  reacting  at  room temperature  the  reaction  was  stopped  by  addition  of
0.05 ml of 10% sodium thiosulfate solution. The reaction mixture was passed through
an anion exchange cartridge (Discovery® DSC-SAX 1 ml, Supelco Analytical,
Pennsylvania, USA) to remove non-reacted 123I-. Eluted solution was purified on
reversed phase (RP) C18 cartridges (Waters, USA). Final eluent was 70 % acetonitrile.
Purification of 123I-chloroquine was improved at the last labeling with addition of a drop
of HCl, which gave a high radiolabeling yield (table 3).
34
The reaction was performed in two equal portions to avoid dilution of phosphate
buffered  saline  (PBS).  Description  above  corresponds  to  a  single  portion.  Finally,  the
product was concentrated in vacuum and dissolved in 2 ml of sterile physiological
saline and taken for animal experiments. Radiolabeling yield and radiochemical purity
of each labeling are collected to the table 3. HPLC traces of radiolabeled chloroquine
are presented in figures 1 and 2 in appendix 2.
Nadolol was radiolabeled with 123I  in a following manner.  To 0.5 ml of 0.5 M sodium
dihydrophosphate buffer (pH 7.4) 0.1 ml of nadolol (75 mg/ml) solution in
MeOH/water (2/1) solution was added. After addition of 0.02 ml of KI solution
(2mg/ml) and 0.17 ml of Na123I (607 MBq) the reaction was started by adding 0.1 ml of
chloramine T solution (8 mg/ml). The reaction mixture was left shaking for 40 min at
70 oC. The reaction was stopped by adding 0.1 ml of 10% sodium thiosulfate solution.
The reaction mixture was passed through an anion exchange cartridge to remove non-
reacted 123I- and the eluted solution was purified on RP C18 cartridges. Final eluent was
70 % acetonitrile. Finally the product was concentrated in vacuum and dissolved in 2 ml
of sterile physiological saline and taken for animal experiments. Radiolabeling yield
and radiochemical purity of each labeling are collected to the table 3. Nadolol presents
as a mixture of four stereoisomers, which are separated during RP HPLC analysis (see
figure 3 in appendix 2).
Table 3. Final activity, radiolabeling yield and radiochemical purity of the final
solutions.
Date Product
Total activity
(MBq)
Activity
(MBq/ml)
Radiolabeling
yield
Radiochemical
purity
7.5.2014 123I-Chloroquine 140 140 28 % 85 %
14.5.2014 123I-Nadolol 158 132 26 % 62 %
21.5.2014 123I-Chloroquine 230 153 31 % 66 %
28.5.2014 123I-Chloroquine 120 120 19 % 94 %
24.9.2014 123I-Chloroquine 557 464 70 % 79 %
1.10.2014 123I-Nadolol 305 203 56 % 68 %
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6.2 Melanin Binding in Vitro
In vitro melanin binding studies were conducted in order to confirm the binding and to
find out if the labeling of the study drugs affects to the binding. Melanin granules used
in this study were separated from RPE and choroid of porcine eyes. Maximum binding
capacities (Bmax)  and equilibrium dissociation constants (Kd) were determined from the
results of binding study.
6.2.1 Isolating Melanin Granules from Porcine Eyes
51 fresh eyes were obtained from slaughterhouse (HK Ruokatalo, Forssa). Eyes were
kept on ice during the transport and cutting procedure. First, extraocular material
(muscles,  eye  lids,  eye  lashes  and  connective  tissues)  was  removed with  scissors,  and
cleaned  eyes  were  stored  in  PBS (pH = 7.4,  Gibco,  Invitrogen,  NY,  USA).  Eyes  were
then  cut  one  by  one  to  separate  the  RPE  and  the  choroid  from  the  other  tissues.  The
sclera was pierced about 5 mm from the limbus with a scalpel and cut with scissors
circumferentially around it. Anterior part of the eye and vitreous was removed. The eye
cup was flipped inside out and the neural retina was gently removed from the posterior
part of the eye. RPE and choroid were detached from the sclera with a scalpel and
placed in PBS. In total, 45 eyes were cut, because in six blue eyes the melanin detached
from the tissues. Separated RPE-choroids were stored in PBS at -20 °C.
Melanin granules were isolated from the RPE-choroids according to Rimpelä (2014).
Tissues  in  PBS  were  heated  to  room  temperature  and  20  mg/ml  solution  of  subtilisin
(Protease, type VIII from Bacillus licheniformis (Sigma-Aldrich, St. Louis, MO, USA))
was added to them. Suspension was incubated at 56 °C for 1 hour with manual stirring
every 10 minutes, heated at 95 °C for 15 minutes and centrifuged at 37 000 g for 15
minutes. Supernatant was removed, the pellet was washed with PBS and centrifuged as
earlier. After removing the supernatant, the pellet was suspended to PBS. Suspension
was vacuum filtered on a Büchner funnel through a filter paper using PBS as a washing
solution, and centrifuged as earlier. Supernatant was removed and the pellet was
suspended to water (Milli-Q®). Suspension was stored at -20 °C.
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In order to freeze dry melanin granules, suspension was heated to room temperature and
froze again with liquid nitrogen. Frozen melanin suspension was lyophilized over night
and dry melanin granules were stored at -20 °C.
6.2.2 Equilibrium Binding Study
Equilibrium binding studies were conducted for chloroquine, nadolol, salicylic acid and
their iodinated pairs (described in chapter 6.1.1). Binding study was also conducted for
salbutamol.
Stock solutions for chloroquine and salbutamol were made in water (Milli-Q®) and for
nadolol, salicylic acid and iodinated compounds in DMSO (Dimethyl Sulfoxide (Sigma-
Aldrich, St. Louis, MO, USA)). For I-chloroquine, a second stock solution was made in
methanol (Sigma-Aldrich, St. Louis, MO, USA) for the analysis. Compound dilutions
of 200 µM, 100 µM, 50 µM, 20 µM, 10 µM, 5 µM, 2 µM, 1 µM and 0.5 µM were made
in PBS (phosphate buffered saline, pH = 7.4) from stock solutions. In the study
solutions, volume of DMSO was less than 1 % in all nadolol and salicylic acid dilutions.
For iodinated compounds, volume of DMSO exceeded 2 % in the highest concentration
and in the other dilutions it was 1 % or less. In addition to compound dilutions, PBS
samples were also prepared in the similar manner with study compounds in order to
evaluate the working accuracy during the experiment.
Melanin suspension was made immediately before the binding study to prevent
aggregation of the granules. 2 mg/ml melanin suspension was made in PBS. Suspension
was warmed to 37 °C and sonicated for 15 minutes to separate the melanin granules. 70
µl of melanin suspension was added to 70 µl of compound solutions on Skirted 96 well
PCR plate with removable 8-strip Flat Caps (4titude, Wotton, Surrey, UK). 70 µl of
PBS was used as a reference. Three replicates were made for all concentrations in
melanin solution and in PBS. The plate was incubated in a shaker (220 rpm) at 37 °C
for 20-24 hours, when equilibrium of the binding was reached. After the incubation,
plate was centrifuged at 4000 rpm for 4 minutes to get all the liquid in the wells.
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Samples were taken to eppendorf tubes and centrifuged at 21 100 g for 15 minutes.
From the supernatant, samples of nadolol, salicylic acid and their iodinated pairs as well
as salbutamol were put into 96-well plate for an ultra performance liquid
chromatography (UPLC) analysis (Aquity UPLC, Waters, Milford, MA, USA) with UV
detection (Photodiode Array Detector, Waters, USA). Details of the UPLC settings are
presented in appendix 2.
Chloroquine and I-chloroquine were further diluted to a mass spectrometric analysis
(Xevo TQ-S, Waters, Milford, MA, USA) combined to UPLC separation (Aquity UPLC,
Waters, Milford, MA, USA) so that the maximum concentration of the compounds were
1 µM. 0.5 µM propranolol solution in acetonitrile/water (1/1) was made as an inner
standard for the analysis. Details of the UPLC-MS settings are presented in appendix 2.
Samples were stored in -20 °C until analysis.
6.2.3 Calculation of Binding Parameters
The binding of drugs to melanin is assumed to occur on the surface of a solid melanin
granule;  therefore Langmuir binding isotherm was used to analyze the results of the in
vitro study (Bridelli et al. 2006; Pitkänen et al. 2007). This isotherm is widely used in
melanin binding studies. Equations of the Langmuir binding isotherm for one (equation
1) and two (equation 2) binding site classes are following:
             (1)
(2)
where B is the observed binding of the drug (ligand) to melanin (nmol/mg), [L] is the
measured concentration of the unbound drug (mM), Bmax is the maximum binding
capacity (nmol/mg), and Kd is the equilibrium dissociation constant (mM). Nonlinear
curve fitting of the binding results was done with SigmaPlot software (version 11.0,
Systat Software, San Jose, CA, USA). Also binding parameters Bmax and Kd were
obtained. The number of binding site classes was evaluated by the goodness of the fit of
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in vitro results to the binding isotherm. The number of binding site classes was
evaluated  also  with  the  Scatchard  analysis,  where  B/[L]  is  plotted  against  B.  A  linear
and concave-up Scatchard plots indicate one and two binding site classes, respectively.
6.3 In Vivo Imaging
This study was approved by Finnish National Animal Experiment Board (permission
number: ESAVI/3631/04.10.03/2012) and conducted according to Good Laboratory
Practices for Animal Research. 12-14 weeks old pigmented inbred Dark Agouti rats
(DA/OlaHsd, Harlan Laboratories, the Netherlands) and albino inbred Fischer 344 rats
(F344/NCrHsd, Harlan Laboratories, U.K.) were quarantined in animal facility for 1-3
weeks before the experiment started. Rats were housed at 22 °C under a 12 h light-dark
cycle.  Commercial  food  pellets  (Teklad  Global  16  %  Protein  Rodent  Diet,  Harlan
Laboratories Inc., USA) and tap water were freely available before and during the
study. At the study day, DA rats weighted 236-281 g and F344 rats 285-295 g.
To avoid 123I labeled drug accumulation into thyroid, 25.6-30.4 mg/ml iodine solution
(Potassium iodide powder (Sigma-Aldrich, St. Louis, MO, USA) in sterile saline
(Sigma-Aldrich Company, U.K.)) was given 9.1-12.9 mg/kg via intragastric injection
for rats one hour prior to drug administration. Rats were maintained under inhalation
anesthesia with isoflurain (Attane vet 1000 mg/g Isofurain, Piramal Healthcare U.K.
Limited, U.K.; Vetflurane 1000 mg/g, Virbac AnimalHealth, Carros, France) in oxygen
gas during drug administration and imaging. Anesthesia induction was made with 4.5 %
isoflurain and maintained with 2-3 % isoflurain. Heated bed in SPECT/CT machinery
maintained body temperature of the animals. 123I labeled drugs were administered
intravenously to the tail vena with catheter needle (26 gauge, BD Neoflon™,
Singapore).
SPECT imaging was performed using a preclinical four-headed gamma ray camera with
1.0 mm multipinhole collimators (NanoSPECT/CT, Bioscan Inc., USA). Anatomical
CT images were acquired with 45 kVp tube voltage X-ray camera in 180 projections. In
total, studies with 123I-chloroquine were conducted with 7 DA rats and one F344 rat.
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Studies with 123I-nadolol were conducted with 3 DA rats and 3 F344 rats. Rats received
23-63 MBq of 123I-chloroquine intravenously in 100-200 µl or 16-82 MBq of 123I-
nadolol intravenously in 100-200 µl. Doses were obtained with dose calibrator
(Capintec Inc. CRC®-25R, New Jersey, USA). Doses of individual rats are gathered to
the table 4.
SPECT  images  were  acquired  from  post-injection  time  points  0  h  with  3  x  15  min
interval (dynamic scan), 4 h, 8 h and 24 h with 30-48 minutes interval (static scan).
Longer intervals for 24 h time points were used in order to get better quality in the
pictures. SPECT scanning was conducted with 24 projections using time per projection
of 18, 20, 40, 50 and 60 seconds for whole body, and 150 and 300 seconds for head
scans. For DA rat 1 in 123I-chloroquine study, whole body SPECT images were acquired
with 32 projections from post-injection time points 20 min with 2 x 20 min interval, 1.5
h with 4 x 20 minutes interval (dynamic scans), and time point 4.5 h with 60 minutes
interval (static scan). Settings of the SPECT scans are summed in table 4. Details of all
scans are included in the table 1 in appendix 4.
Table 4. SPECT settings in experiments and doses of individual rats. DA = Dark Agouti
rat (pigmented); F344 = Fisher 344 rat (albino)
123I-Chloroquine experiments
Rat Dose (MBq) Proj. Time/ Proj. (s) Scan type
DA Rat 1 23 32 60 Biodistribution
DA Rat 2 54 24 18–50 Biodistribution
DA Rat 3 63 24 20–50 Biodistribution
DA Rat 4 52 24 20 Biodistribution
DA Rat 5 49 24 20–60 Biodistribution
DA Rat 6 56 24 20–60 Biodistribution
DA Rat 7 59 24 20–40 Biodistribution
F344 Rat 1 57 24 18–50 Biodistribution
123I-Nadolol experiments
Rat Dose (MBq) Proj. Time/ Proj. (s) Scan type
DA Rat 1 57 24 18–50 Biodistribution
DA Rat 2 82 24 150–300 Head & eyes
DA Rat 3 37 24 150–300 Head & eyes
F344 Rat 1 20 24 20–60 Biodistribution
F344 Rat 2 16 24 20–60 Biodistribution
F344 Rat 3 39 24 150-300 Head & eyes
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The SPECT images were reconstructed with HiSPECT NG software (Scivis GmbH,
Germany) and CT images with CTReco (Bioscan Inc., USA). After reconstruction,
images were fused and analyzed with VivoQuant® (Bioscan Inc., USA). Volumes of
interests (VOI’s) were drawn manually to the areas of assumed melanin binding.
Activity within each VOI were recorded, corrected for radioactive decay and
normalized to the activity at the time of injection.
7 RESULTS
7.1 Melanin Binding in Vitro
Melanin binding of chloroquine, nadolol, salicylic acid and their iodinated pairs were
determined. Binding was also studied with salbutamol. Results of the equilibrium
binding study are presented in table 5 and figure 12. No results were obtained from I-
chloroquine due to technical difficulties in UPLC-MS equipment. Chloroquine shows
the highest binding (up to 99.7 %), whereas salicylic acid and I2-salicylic acid bind the
least (7.5 and 4.5 %). Binding of nadolol and salbutamol is rather similar showing
binding of 11-22 % and 10-18 %, respectively. According to the results, iodination of
nadolol and salicylic acid increases their melanin binding significantly. Binding
increases with iodination to 5-fold for nadolol and to 3-fold for salicylic acid with the
highest concentration (100 µM), which is seen in the figure 12.
Table 5. Fraction bound (%) of studied drugs with concentration rate that gave positive
binding.
Study drug Concentration range (µM = µmol/l) Fraction bound (%)
Chloroquine 0.25–100 96–99.7
Nadolol 0.25–100 11–22
I-Nadolol 0.25–100 50–81
Salicylic acid 2.5–100 0.5–7.5
I2-Salicylic acid 0.5–100 2-4.5
Salbutamol 1-100 10–18
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Binding parameters for chloroquine, nadolol, I-nadolol and salbutamol were obtained
with nonlinear curve fitting of Langmuir binding isotherm (table 6). P-values of the
parameters  were  <  0.05  for  all  one  site  binding  models.  For  salicylic  acid  and  I2-
salicylic acid, no binding parameters were obtained because of poor fitting to the model.
For two site binding models, only chloroquine parameters had P values of < 0.05.
Results  with  P  value  of  1  are  not  presented  in  the  table.  R2 values  were  >  0.98  in  all
reported cases.
Table 6. Binding parameters for chloroquine, nadolol, I-nadolol and salbutamol
obtained with nonlinear curve fitting of Langmuir binding isotherm. For salicylic acid
and I2-salicylic acid no reliable parameters were obtained. Standard errors are shown in
parentheses.
One site binding model
Chloroquine1 Nadolol1 I-nadolol1 Salbutamol1
Bmax (nmol/mg) 111 (6.0) 29.7 (6.9) 117 (21) 18.3 (1.5)
Kd (µM) 0.71 (0.12) 170 (54) 64 (19) 71.6 (10.7)
Two site binding model
Chloroquine1 Nadolol I-nadolol Salbutamol
Bmax (nmol/mg) 36 (7.7) No fit (P=1) 10.3 (5.1) 8.2 (7.6)
Kd (µM) 0.11 (0.03) 2.2 (1.6) 71.6 (125)
Bmax2 (nmol/mg) 106 (6.9) 452 (880) 10.1 (7.4)
Kd2 (µM) 3.06 (1.2) 503 (1140) 71.6 (99)
1 P values of the parameters were < 0.05
R2 values were > 0.98 in all reported cases
Scatchard plots for binding of chloroquine, salbutamol, nadolol and I-nadolol are
presented in figure 13. Since salicylic acid and I2-salicylic acid showed no or very small
binding, Scatchard analysis was not performed to them. According to graphs in figure
13, chloroquine and I-nadolol represent concave-up Scatchard plots indicating two
binding site classes. Concave-up plot is also possible for nadolol, because there is only
one data point deviating from the line. For salbutamol, no clear results can be obtained
from Scatchard analysis.
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Figure 12. Melanin binding of nadolol and I-nadolol, salicylic acid and I2-salicylic acid,
and chloroquine and salbutamol are represented on linear scales (upper graphs and
middle graph) and on log-log scale (lower graph). Error bars represent 5 % standard
error, which is typical error for in vitro experiments. Standard deviation of replicate
samples did not exceed 5 %. Error bars are not presented in log-log scale.
43
Figure 13. Scatchard plots for binding of chloroquine, salbutamol, nadolol and I-
nadolol.
7.2 In Vivo Imaging
Distribution and elimination of two melanin binding drugs with different
physicochemical properties were studied in pigmented and albino rats with SPECT/CT.
Anatomical pictures were obtained with x-ray scan on CT mode and functional pictures
with gamma ray scan on SPECT mode.
7.2.1 123I-Chloroquine Study
Distribution of 123I-chloroquine after intravenous injection was studied with seven
pigmented rats and one albino rat, which was the reference for the melanin binding.
Drug distribution in pigmented rat 1 was studied in different time points than the other
rats. Therefore it is presented separately in figure 14. At the first time point, drug is
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distributed into the liver and the bladder. A significant amount of the drug is seen in the
eyes, especially in the posterior part.  At the later time points, drug accumulation in the
feces and the spleen is seen. Rat died due to overdose of isoflurain after the time point
4.5 h, so no further images were obtained. Accumulation of 123I-chloroquine in the eyes
is seen in all images. CT image of the first scan is not available, because the rat woke up
during the imaging. Therefore the SPECT images of the first scan (20 and 40 min) are
appended on the CT obtained from the second scan.
Figure 14. Distribution of 123I-chloroquine after intravenous injection of pigmented rat
1.  Drug  distributes  to  the  liver,  urine,  feces,  the  spleen  and  the  eyes.  CT image  of  the
first scan (20 and 40 min) is not available, so it is replaced with CT of the second scan.
Pictures are made with VivoQuant® program.
Additional scans were conducted with new rats. Unfortunately, injections to pigmented
rats 2, 3, 4, and 7 failed despite professional personnel. No results were obtained from
these scans. Injection to pigmented rat 5 was rather successful, although some
radioactivity  is  seen  on  the  tail  and  at  the  injection  site.  Pictures  from  this  rat  are
compared to pictures obtained from albino rat in figure 15. Distribution of 123I-
chloroquine in pigmented and albino rats follows the same pattern. During the first 45
minutes (first 3 images), drug distributes into liver, bladder, spleen and the eyes. Drug is
also seen in kidneys at the time point 0 h in the albino rat. At the time points 4 and 8 h,
drug continues accumulating into the spleen, but it is also present in the bladder, the
feces  and  the  eyes.  At  the  time point  24  h,  drug  is  concentrated  in  the  spleen  of  both
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rats. In albino rat it is also in the thyroid glands. 123I-chloroquine is clearly located also
in the posterior part  of the eyes in pigmented rat  whereas it  is  absent from the eyes of
albino rat.
Figure 15. Distribution of 123I-chloroquine in pigmented rat and albino rat. Distribution
follows  same  pattern  in  both  rats  despite  the  time  point  24  h.  Drug  is  retained  in  the
eyes of the pigmented rat  whereas it  is  absent from the eyes of albino rat.  Pictures are
made with VivoQuant® program.
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A closer look to the eyes and the head is presented in figure 16, which reveals sagittal,
frontal and horizontal slices of the left eye from pigmented rat 5 and albino rat after 123I-
chloroquine  administration.  In  pigmented  rat,  drug  accumulation  in  the  eyes  becomes
detectable during first 15 minutes post injection. The drug locates in the posterior part
of the eyes and Harder’s glands whereas in albino rat drug is more widely distributed
into the tissues, except for the brains. Small accumulation in the Harder’s glands is
detected also in albino rat until the time point 8 h. 123I-chloroquine is clearly located in
the  uveal  tract  of  the  pigmented  rat  24  h  post  injection,  whereas  in  the  albino  rat  it  is
only seen in the thyroid glands.
Figure 16. Sagittal, frontal and horizontal slices of the left eye from pigmented rat and
albino rat after 123I-chloroquine administration. During the first 15 minutes, drug locates
in the eye of the pigmented rat on a detectable amount. It is still retained there at the last
time point. Drug accumulation in the Harder’s glands is seen in albino rat until the time
point 8 h. At the time point 24 h, drug is only seen in the thyroid glands, but not in the
eyes of albino rat. Pictures are made with VivoQuant® program.
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The VOI’s were drawn at the highest activity in the eye area, which is seen in the figure
16. Thus, in pigmented rats, the VOI’s of the time points 0-8 h represent the activity in
the posterior part of the eyes and the Harder’s glands, and the last time point the activity
only  in  the  posterior  part  of  the  eyes.  In  albino  rat,  VOI’s  were  drawn at  the  Harder’s
glands. The graph in the figure 17 represents the average activity normalized for the
dose and the standard deviation of VOI’s from pigmented rats 5 and 6 compared to the
activity in albino rat plotted against time. The pigmented rat 1 was not used in the VOI
analysis due to different time points. The highest activity was achieved at 4 hours after
injection. The average area of the activity in the eyes and Harder’s glands of pigmented
rats was 160 mm3 varying from 205.8 (first time point) to 125.4 mm3 (last time point).
Average area of the activity in Harder’s glands of albino rat was 56.9 mm3 varying from
28.9 (8 hours post injection) to 181.4 mm3 (4 hours post injection). Raw data of the VOI
analysis is provided in appendix 5.
Figure 17. Average activity of the eyes of pigmented and albino rat normalized for the
dose. Error bars of pigmented rat represent standard deviation between subjects (n=2)
and error bars of albino rat represent standard error of 20 %, which is typical for animal
studies.
7.2.2 123I-Nadolol Study
Distribution of 123I-nadolol after intravenous injection was studied with three pigmented
rats and three albino rats. None of the injections to albino rats were completely
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successful,  but  the  pictures  of  rat  2  are  shown  here  as  reference  to  give  some
comparison for pigmented rats. Distribution of 123I-nadolol in the pigmented rat 1 and
the albino rat 2 are represented in the figure 18. Fast distribution of the drug to the
spleen and urine is seen in pigmented rat. With low contrast, one can not see any
localization in melanin containing tissues. Rat died due to overdose of isoflurain after
the time point 4 h, so no further images were obtained. In albino rat, most of the drug is
distributed  from  the  tail  to  the  feces.  At  the  last  time  point,  almost  the  whole  dose  is
cleared from the body.
Figure 18. Distribution of 123I-nadolol in pigmented rat and albino rat. Drug is mainly
located  in  the  spleen  and  urine  of  the  DA rat.  Some accumulation  in  the  feces  is  also
seen. In albino rat, most of the drug is distributed from the tail to feces. No activity at
the time point 24 h is seen.
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Even though melanin binding in pigmented rat is not seen in the figure 18 at low
contrast, it is clearly visible in sagittal and frontal slices at 4 h post injection with high
contrast (figure 19). 123I-nadolol accumulates to the fur of pigmented rat, which can not
be seen in any images of albino rat (images not shown here). Figure 20 represents the
distribution of the drug in the head area of pigmented rat 2 and albino rat 2. Significant
amount of the drug is present in the nasal cavity of the pigmented rat. Similar
distribution  is  seen  in  the  pigmented  rat  3  (images  not  shown  here).  At  24  h  post
injection, 123I-nadolol is concentrated to the olfactory epithelium of the nasal cavity.
Same kind of accumulation of the drug can not be seen in the pictures of albino rat.
Figure 19. 123I-nadolol  accumulation  to  the  fur  in  pigmented  rat  at  the  time point  4  h.
Upper image represents the sagittal slice of the rat and lower the frontal slice.
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Figure 20. Localization of 123I-nadolol in the nasal cavity of pigmented rat. Sagittal,
frontal  and  horizontal  slices  of  the  nasal  cavity  from  pigmented  rat  and  albino  rat  are
presented.
Results of the VOI analysis are presented in figure 21, which shows the average activity
normalized for the dose and the standard deviation of VOI’s from pigmented rats 2 and
3. 123I-nadolol did not accumulate to the nasal cavity of albino rats; therefore VOI’s
were not possible to drawn from them. Average area of the activity in the nasal cavity
was 213.7 mm3 varying from 84.5 (first time point) to 275.2 mm3 (4 h post injection).
However, due to anesthesia maintained with inhalation mask, the range of the image
does not cover the whole nasal cavity. Raw data of the VOI analysis is provided in
appendix 5.
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Figure 21. Average activity of the nasal cavity of pigmented rats normalized for the
dose. Error bars represent standard deviation between subjects (n=2).
8 DISCUSSION
8.1 In Vitro Study Setting
As described in chapter 4.1, according to Pitkänen et al. (2007) melanin source affects
to the binding results. In this study, melanin separated from porcine RPE-choroids was
used. Other sources used in melanin binding studies include e.g. rabbit or bovine RPE-
choroid melanin, Sepia melanin and synthetic melanin (Kaliszan et al. 1993; Bridelli et
al. 2005; Pitkänen et al. 2007; Kadam et al. 2011). Human eye melanin is rarely used.
Pitkänen et al. (2007) argued, that melanin from natural source will give more reliable
results than synthetic melanin. Comparative studies of the surface area and melanin
composition at the surface would be useful in order to extrapolate results to humans.
Melanosomal pH is expected to be acidic in the RPE. However, the binding studies
were conducted at physiological pH 7.4., which corresponds better to the skin
melanocytes, where active melanogenesis occurs. The pH affects to the ionization of
weak asids and bases, and therefore their binding characteristics to melanin. Rimpelä
(2014) studied the melanin binding of weak acids methotrexate and
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carboxydichlorofluorescein (CDCF) in pH 5 and 7.4., and noticed that pH had
significant effect to the binding. Melanin binding increased while there were more
molecules in their neutral form instead of acidic form. Because melanin has a
polyanionic structure, this kind of behavior is expected. Acidic drugs with lower pKa
values than 7.4. are not expected to pass the lipid membrane of melanosome, because
they are in their ionized form outside the organelle. This is the same for basic drugs that
have higher pKa value than 7.4, however also lipophilicity and molecular weight are
important determinants in passive permeation. Therefore Rimpelä suggests that binding
studies conducted at pH 5 give a better information of the intrinsic interaction between
melanin and the drug whereas studies done at physiological pH correspond better to the
in vivo situation. In addition to pKa, lipophilicity and molecular weight of the drug,
transporters can take part in the passage through melanosomal membrane. A little
information exists on transporters in melanosomes. Organic anion transporter MRP4 has
been found from porcine RPE, but the function of the transporter in melanosome is still
unknown (Azarian et al. 2005).
8.2 In Vitro Study Results
Melanin binding study was conducted to chloroquine, nadolol, salicylic acid and their
iodinated pairs. Salbutamol was studied first as a non-binding reference, but it was
changed to salicylic acid due to contradictory data of melanin binding properties (Sauer
and Anderson 1994; Howells et al. 1994). As expected based on literature, chloroquine
showed the highest binding to melanin (Ings 1984; Ono et al. 2003; Rimpelä 2014). The
binding of two hydrophilic drugs, nadolol and salbutamol (logP = 0.7 and 0.3,
respectively), was rather similar showing moderate binding. As expected for negative
control, salicylic acid showed low or negligible binding.
Binding parameters Bmax and Kd were obtained with nonlinear curve fitting of binding
results in Langmuir binding isotherm (equations 1 and 2 in chapter 6.2). In the
literature, results are fitted to either one or two site binding model without comparison
of these two models (Koeberle et al. 2003; Pitkänen et al. 2007). Selection of the model
can be done for example based on Scatchard plot or the simplest model that fits.
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Parameters from both models have also been compared (Rimpelä 2014). The results of
chloroquine from this study correspond to the results from Rimpeläs study. Two binding
site classes are indicated by both Langmuir binding isotherm and Scatchard plot in both
studies. For nadolol, P value was 1 for two binding site model indicating poor
reliability, therefore the parameters were not presented in this study. Parameters for two
binding site model were included in Rimpeläs study based on goodness of the fit to the
model,  but  the  P  values  were  not  reported.  Scatchard  plot  of  nadolol  did  not  give  any
results in either of the studies. For I-nadolol and salbutamol, Langmuir binding isotherm
results indicate one site binding model, whereas Scatchard plot analysis indicates two
binding site classes for I-nadolol. Scatchard plot did not give results for salbutamol.
Since Scatchard analysis is rather old and linear analysis method, nowadays it is
recommended that nonlinear computational methods should be used. Thus, the number
of binding site classes gained with Langmuir binding isotherm can be considered more
reliable than Scatchard analysis.
Recently, Rimpelä (2014) studied melanin binding of chloroquine and nadolol with the
same study methods. Her study included a comparative table of the binding parameters
from the literature. As such, parameters were not well comparable due to great variation
in  the  values.  Even  the  results  obtained  in  this  study  did  not  show  similar  parameter
values, despite the same study methods. Concentration range in this study was 0.25-100
µM (n=9) whereas in Rimpeläs study it was 0.25-500 µM (n=11), which can be the
reason for different values of the parameters. As Rimpelä argued in her study, great
variation in Bmax and Kd values  can  be  also  a  result  of  different  melanin  sources  or
separation methods, assay conditions (e.g. incubation time, pH) or analytical methods.
Iodine (123I) was chosen as a radioactive label for SPECT/CT studies, because as a small
radiotracer it causes a minimal change in the chemical structure of chosen compounds.
Molecular iodine is a slightly water-soluble halogen having electronegative value of 2.5
in Pauling scale. Effect of iodination to melanin binding was studied with non-
radioactive I-labeled compounds. Iodine was attached to ortho-position of aromatic
rings of chloroquine and nadolol. Two iodine molecules were attached to aromatic ring
of salicylic acid forming 3,5-I2-salicylic acid. Iodination of nadolol and salicylic acid
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raised their melanin binding 5-fold and 3-fold with the highest concentrations (100
µM), respectively. There are two characteristic features of iodine that can explain this.
Electronegativity of iodine pulls delocalized electrons of the benzene ring towards itself
making the molecule more reactive. According to the literature, aromatic iodination
increases the logP value of compounds ca. 1 logP unit making them more lipophilic
(Wermuth 2003). It is has been widely studied that basic and lipophilic drugs bind to
melanin (Ings 1984; Leblanc et al. 1998). Therefore it is reasonable that binding
increases with iodination. It also explains why I2-salicylic acid shows negligible binding
to melanin despite iodination whereas basic I-nadolol binds significantly. Melanin
binding of I-nadolol or I2-salicylic acid has not been studied before, so results were not
possible to compare to the literature.
Comparative results of the melanin binding of chloroquine and I-chloroquine were not
gained in this study due to technical difficulties in UPLC-MS equipment. There are no
in vitro melanin binding studies with iodinated chloroquine. However an early study
describes that iodination of chloroquine derivative does not change its melanin binding
in vivo. Research group studied distribution of 125I-labeled (half life 59 days)
chloroquine derivative compared to Na125I in Syrian hamster expressing malignant
melanoma  (Beierwaltes  et  al.  1968).  Na125I did not accumulate in melanin containing
tissues whereas iodinated chloroquine derivative did. These results are not comparable
to in vitro studies, but according to them iodination of chloroquine derivative does not
prevent melanin binding.
8.3 In Vivo Study Setting
Distribution of 123I-chloroquine and 123I-nadolol was studied in inbred pigmented DA
rats and inbred albino F344 rats in order to find out if melanin binding can be studied in
vivo with SPECT/CT imaging method. Comparative studies with pigmented and albino
animals have been conducted successfully with WBA and tissue isolation method, as
described in chapter 4.2. Several different rat strains have been used in the studies,
including pigmented LE, DA, ACI and BN rats (Kasuya et al. 1975; Gygi et al. 1996;
Slawson et al. 1998; Ono et al. 2003). SD rat is the most often used albino rat in
55
melanin binding studies. The DA rat possesses brown agouti hair and black eyes.
Whether the strain has pigment in other tissues is not known, even though melanin has
been detected also from the inner ear, spleen, heart and pulmonary vein of rodents. As
melanin is absent in albino rat, theycan be used as a reference for melanin binding. The
quantity of melanin in the tissues of DA or F344 rats was not evaluated in this study.
Also sensitivity of the rats to the anesthetic can vary between the strains and individual
rats, so careful dosing of the anesthetic is required.
Chloroquine and nadolol were labeled with 123I  prior  to  animal  experiments.  As
presented in the table 3 in the chapter 6.1.2, a radiolabeling yield varied between 19-70
% for 123I-chloroquine and 26-56 % for 123I-nadolol. Compounds tended to attach to the
RP C18-column giving rather low yields. Purification of 123I-chloroquine was improved
with addition of HCl to the buffer at the last labeling, which gave the highest yield.
Labeling yield determined the number of animals in the SPECT/CT study varying from
1 to 3 per study day. Radiochemical purity was 66-94 % for 123I-chloroquine and 62-68
% for 123I-nadolol showing great variation in the purity of 123I-chloroquine. For either of
the drugs, the remaining compounds were not determined. They can be e.g.
polymerization products or other iodinated compounds, since 123I can attach to the
aromatic  ring  in  several  positions.  As  labeled,  these  compounds  are  detected  with  the
SPECT among the right compounds. Because 123I- was removed in an anion exchange
cartridge, it should not be remained in the final solution. In order to gain a better
labeling yield and a radiochemical purity, which determine the conditions for animal
studies, enough time must be reserved for the labeling optimization.
In SPECT/CT study, four-headed gamma ray camera with 1.0 mm multipinhole
collimators was used. According to the manufacturer, a resolution of < 0.75 mm is
obtained with these collimators. CT setting was the same in all scans giving reliable
comparison of the images. SPECT scanning was conducted with 24 projections in all
scans with varying time per projection of 18, 20, 40, 50 and 60 seconds for whole body
and 150 and 300 seconds for head scans, depending on the time point. Slight variation
in the whole body scans can cause small deviation on the accuracy of the images. Doses
shown in the table 4 in chapter 6.3 represent the injected activity. However, due to lack
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of completely succeeded injections, these doses do not represent the right amount given
intravenously. In most of the injections, some traces of the dose were left at the
injection site. Thus, the numbers normalized with the dose are not reliable, although
they are comparable with each other.
SPECT/CT imaging method provides many advantages and possibilities. Instead of
focusing in specific tissues, it can give a comprehensive picture how the radiotracer
localizes in the whole body. The number of subjects can be radically decreased, because
the same rat can be studied in several time points. Three-dimensional as well as planar
images are obtained after computational image reconstruction, which enables detection
of even unexpected localizations of the radiotracer. However, SPECT/CT is only a
semi-quantitative method, and therefore quantitative methods, e.g. gamma-counting or
biochemical methods, should be included to the study in order to have more accurate
data.
8.4 In Vivo Study Results
Distribution of 123I-chloroquine and 123I-nadolol was followed in pigmented and albino
rats with SPECT/CT imaging method against the time. According to the literature, half
of the chloroquine dose is excreted via kidneys as unchanged and the rest as metabolites
in humans (MicroMedex 2014). Nadolol is excreted unchanged via kidneys in humans.
As seen in whole-body figures 14 and 15 in the chapter 7.2.1, 123I-chloroquine
accumulates into the liver, feces, kidneys and urine, which corresponds to the literature
indicating similar elimination pattern of iodinated chloroquine in rats. In the whole-
body figure 18 in the chapter 7.2.2, 123I-nadolol is  concentrated in urine and spleen of
the  pigmented  rat  whereas  it  is  absent  from  the  liver,  which  also  corresponds  to  the
human  elimination  data  of  nadolol.  Images  of  the  albino  rat  after 123I-nadolol
administration represent subcutaneous injections to the tail due to unsuccessful
injection; therefore they are not comparable to images of the pigmented rat.
Chloroquine is metabolized in humans from its aliphatic carbon chain. Thus, it is
believed that 123I is not cleaved out in the metabolism and only 123I-chloroquine and its
57
metabolites  are  followed  with  SPECT.  However,  metabolites  of 123I-chloroquine were
not determined in this study.
The main objective of this study was to demonstrate if melanin binding can be observed
in vivo with SPECT/CT imaging method. It was shown, that 123I-chloroquine
accumulated highly in the posterior part of the eye in pigmented rats, but not in the
albino rat. Melanin is highly concentrated in the posterior part of the eyes, in the RPE
and the uveal tract. The drug was retained there in pigmented rats until 24 h post
injection indicating binding to melanin. In the albino rat, the drug was not seen at the
eyes  24  h  post  injection.  Whether  the  drug  localizes  in  the  RPE  or  the  choroid  of
pigmented rats can not be told based on the images, because the monolayer of RPE cells
is too thin to be detected with an accuracy of the SPECT. In other studies, accumulation
of 14C-chloroquine in the fur has been described with BN and ACI rats, as well as in the
testicles with BN rat (Kasuya et al 1975; Ono et al. 2003). This accumulation was not
seen in this study with DA rats. Since iodination increases the logP value, it can change
the  distribution  pattern  of  the  original  drug.  This  difference  can  also  result  from  the
different rat strains used. During the first 4 h, 123I-chloroquine localizes to the Harder’s
glands showing high accumulation there. It also localizes clearly in Harder’s glands of
albino rat. This kind of localization has been described also in the literature with 14C-
chloroquine, even at 24 h after intravenous injection (Kasuya et al 1975). In this study,
123I-chloroquine  was  not  detectable  in  the  Harder’s  glands  at  the  time  point  24  h  in
either of the rats. The Harder’s gland, which secretes lipids, porphyrins and indoles,
covers the whole posterior part of the eye in rats (Payne 1994). Also melanocytes have
been detected from the Harder’s glands of mouse, but there is no literature of it in rats
or humans. Lipophilic drugs penetrate easily to the lipid matrix of the gland; therefore
accumulation is seen in both rat strains.
123I-nadolol was seen to accumulate in the fur of the pigmented rat at the time point 4 h.
No reliable images were gained from albino rats; therefore there is no proper reference
for melanin binding of 123I-nadolol. However, it can be assumed that accumulation in
the fur was due to melanin binding. There is no literature of this with nadolol, but
instead several studies of other drugs that bind to skin or hair melanin (e.g. salbutamol,
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codeine) (Gygi et al. 1991; Vulic et al. 2011). As shown in melanin binding studies,
123I-nadolol binds to melanin in vitro 5-fold more than non-iodinated nadolol. Thus,
these results are not straight comparable to nadolol. 123I-nadolol was not retained in the
melanocytes of the choroid, but high accumulation in the nasal cavity was detected.
There is an early article suggesting that the pigment in nasal cavity is localized in the
supporting cells and Bowman’s gland, but not in olfactory cells (Takagi and Yajima
1965). However, there is no literature available if this pigment is melanin or other
pigment. Also, there is no mention of the nasal cavity in the reviews of melanin function
and distribution (Tolleson 2005; Dubey and Rowlin 2014). As melanin is known to bind
ROS and chemicals, it is possible that it is located also in the nasal cavity, where
potentially toxic chemicals can come via the air. Melanin locates in normal conditions
of humans close to sensory neurons: the eye, the vestibular organ and the cochlea of the
ear and the skin. Only in the mouth melanocytes are located in the buccal mucosa
instead of close to the sensory neurons of the tongue. This further supports the
possibility  of  melanin  localization  in  the  nasal  cavity  of  the  pigmented  rat.  Additional
studies on melanin distribution in humans and study animals are required for more
profound discussion on this topic.
VOI’s were drawn manually at the highest activity in the eye area and the nasal cavity.
Activity within each VOI were recorded, corrected for radioactive decay and
normalized to the activity at the time of injection. As stated earlier, due to unsuccessful
injections  the  numbers  normalized  with  the  dose  are  not  reliable,  but  they  are
comparable with each other. Due to high melanin binding and long half life, there are no
enough data points to the elimination curve of 123I-chloroquine. Only the two last time
points could be included in the elimination curve. Other isotopes of iodine, e.g. 131I (half
life 8 days) or 125I (half life 59 days) can be considered to further studies to give longer
time points for kinetic profiling. Distribution to the eyes is rather fast happening during
the first 15 minutes. Thus, multiple shorter scans are needed to show the beginning of
the  accumulation.  The  diameter  of  a  schematic  rat  eye  is  6.41  mm and the  volume of
whole eye is 132.7 mm3 (Hughes  1979).  The  average  volume  of  the  VOI’s  was  160
mm3 varying from 205.8 (first time point) to 125.4 mm3 (last  time  point).  These  are
rather large areas compared to the thin uveal tract. Inclusion of the Harder’s glands into
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the VOI’s raises the area. Also there can be scattering of the activity, which is included
in the VOI’s. More accurate images are possible to obtain by increasing the number of
projections or using smaller multi-pinhole apertures. With 0.6 mm apertures, an
accuracy of < 0.45 mm is achieved according to the manufacturer. It is also possible to
draw  spherical  VOI’s  to  the  specific  area  of  the  eye  instead  of  VOI’s  covering  the
highest activity. This optional method, which was not used in this study, would give an
activity depicting only the eye area.
Localization of 123I-chloroquine to the uveal tract was clearly seen in pigmented rats
whereas 123I-nadolol did not accumulate to the eyes at any extend. The most striking
difference  in  terms  of  physicochemical  properties  between  these  two  drugs  is  their
lipophilicity. LogP values of chloroquine and nadolol are 4.6 and 0.7, respectively.
Iodination increases the values ca. 1 logP unit (Wermuth 2003). As melanin binding
increases with the lipophilicity, it seems that also the access from the circulation to the
uveal melanin increases. Lipophilic drugs can pass blood-retina-barrier and lipid
membranes, and therefore access into melanosomes of the RPE. The reason why 123I-
nadolol did not accumulate to the melanocytes of the choroid is not known, but it can be
due to low lipophilicity. Lipid containing Harder’s gland surrounds the posterior of the
eye and might prevent accumulation of hydrophilic compounds. Lipophilic drugs that
bind to melanin are known to access to the brains in humans (Salazar et al. 1978). This
localization can not be detected in rats, but it is an important issue considering systemic
delivery of melanin targeted drugs.
9 CONCLUSIONS
This study is the first to demonstrate, that SPECT/CT imaging method can be used to
study melanin binding in vivo by comparing distribution of the study compound
between pigmented  and  albino  rat.  Iodine  radiotracers  are  a  relevant  choice  of  gamma
radiators for melanin binding studies, because they do not prevent melanin binding.
Because aromatic iodination changes electronegative properties and raises logP value of
compounds, melanin binding increases with iodination. Thus, the effect of the tracer to
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the physicochemical properties of the compound and melanin binding should be
determined in vitro. Other isotopes can be considered to further studies to give longer
time points for kinetic profiling. Because SPECT/CT is a semi-quantitative method,
quantitative methods, e.g. gamma-counting, should be incorporated to the study in order
to have more powerful data. Additional studies are needed for statistical analysis.
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APPENDIX 1. HNMR SPECTRAS OF IODINATION PRODUCTS
Figure 1. HNMR spectra of 3-iodo-chloroquine.
Figure 2. HNMR spectra of 2-iodo-nadolol.
Figure 3. HNMR spectra of 3,5-diiodo-salicylic acid.
APPENDIX 2. ANALYSIS SETTINGS
HPLC settings in isolation of iodinated nadolol and salicylic acid
HPLC Hewlett Packard 1050, Colorado, USA
Column C18 (2.5 x 25 cm) (Waters, USA)
Injection volume 20 μl
Linear gradient mode
Mobile phase:
A – 0.1 % trifluoroacetic acid (Tfa) in water
B – 0.1 % Tfa in 80% MeCN from 5 to 55 % of B
Duration 30 min
UPLC-UV settings in isolation of compounds in melanin binding experiment
Aquity UPLC, Waters, Milford, MA, USA
UV Photodiode Array Detector, Waters, USA
Column UPCL HSS T3 (1.8 μm, 2.1 x 50 mm) (Waters, USA)
Injection volume 10 μl
Gradient mode
Mobile phase: acetonitrile/15 mM phosphate buffer (pH 2)
Duration 3-5 minutes depending on the sample at 30 ºC
UPLC-MS settings in isolation of compounds in melanin binding experiment
Aquity UPLC, Waters, Milford, MA, USA
Xevo TQ-S triple quadrupole with electrospray ionization MS, Waters, Milford, MA, USA
Column UPLC HSS T3 (1.8 μm, 2.1 x 100 mm) (Waters, USA)
Injection volume 0.5 μl
Gradient mode (UPLC), positive mode (MS)
Mobile phase: acetonitrile (0.1 % formic acid)/water (0.1 % formic acid)
Duration 3-5 minutes depending on the sample at 25 ºC
APPENDIX 3. HPLC TRACES OF RADIOLABELED PRODUCTS
Figure 1. HPLC traces of radiolabeled Chloroquine.   A - 0.05 M NaH2PO4 buffer, B –
0.05 M  NaH2PO4 buffer in 70% MeCN, pH = 5.0. Linear gradient from 0 to 70% B in
30 min.
Figure 2. HPLC traces of radiolabeled Chloroquine.   A - 0.05 M NaH2PO4 buffer, B –
0.05 M  NaH2PO4 buffer in 70% MeCN, pH = 5.0. Linear gradient from 0 to 55% B in
30 min.
2Figure 3. HPLC traces of radiolabeled Nadolol.   A - 0.05 M NaH2PO4 buffer, B – 0.05
M  NaH2PO4 buffer in 70% MeCN, pH = 5.0. Linear gradient from 0 to 55% B in 30
min.
APPENDIX 4. Details of the SPECT/CT scans
Table 1. Details of the scans concluded in this study.
APPENDIX 5. Raw data of the VOI analysis
Table 1. Raw data of the VOI analysis of pigmented DA rats 1, 5 and 6 and albino F344
rat in 123I-chloroquine study.
Dose
(MBq
)
Time
point
(h)
Left
Eye
(MBq
)
Right
Eye
(MBq
)
Correcte
d values
left eye
(MBq)
Correcte
d values
right eye
(MBq)
Area
left
(mm3
)
Area
right
(mm3
)
% of
dos
e
Averag
e (% of
dose)
St.
Dev
(% of
dose
)
Standard
deviatio
n
Pigmented DA rat 1
23 0.33 0.063 0.074 0.064 0.075 180.9 205,8 0.61 0.000006
0.66 0.066 0.074 0.068 0.077 180.3 191,7 0.63 0.000010
1.50 0.070 0.071 0.076 0.077 179.6 185,9 0.66 0.000004
2.50 0.074 0.072 0.085 0.082 183.3 182,6 0.73 0.000005
4.50 0.053 0.056 0.067 0.071 151.7 163,5 0.60 0.000004
Pigmented DA rat 5
49 0.25 0.058 0.068 0.059 0.069 174.3 205,3 0.26 0.25 0.01 0.000037
0.5 0.059 0.061 0.061 0.063 157 164,1 0.25 0.28 0.03 0.000061
0.75 0.068 0.063 0.071 0.066 169.6 162,8 0.28 0.31 0.03 0.000067
4 0.073 0.068 0.090 0.084 153.9 150,5 0.36 0.34 0.02 0.000011
8 0.034 0.033 0.052 0.051 149.8 145,2 0.21 0.25 0.04 0.000104
24 0.012 0.012 0.044 0.044 149.6 149,7 0.18 0.20 0.02 0.000089
Pigmented DA rat 6
56 0.25 0.072 0.065 0.073 0.066 176.4 161,3 0.25
0.5 0.083 0.09 0.085 0.092 165.8 186,8 0.32
0.75 0.092 0.095 0.096 0.099 179.5 178,7 0.35
4 0.077 0.068 0.095 0.084 164 145 0.32
8 0.05 0.054 0.077 0.083 143.5 144,1 0.28
24 0.018 0.017 0.065 0.061 142.8 125,4 0.22
Albino F344 harders glands
57 0.25 0.021 0.021 0.021 0.021 32 32 0.07
0.5 0.02 0.02 0.021 0.021 29 29 0.07
0.75 0.037 0.037 0.039 0.039 48.4 48.4 0.14
4 0.055 0.044 0.068 0.054 181.4 146.2 0.21
8 0.007 0.007 0.010 0.010 28.9 28.9 0.03
24 no activity
2Table  2.  Raw  data  of  the  VOI  analysis  of  pigmented  DA  rats  2  and  3  in 123I-nadolol
study.
Dose
(MBq)
Time
point (h)
Nasal cavity
(MBq)
Corrected
values
(MBq)
Area
(mm3) % of dose
Average %
of dose
St.Dev % of
dose
Pigmented DA rat 2
82 0.25 0.018 0.018 84.5 0.022 0.092 0.0496
0.50 0.067 0.069 260.0 0.082 0.152 0.0520
0.75 0.087 0.091 270.0 0.106 0.163 0.0432
4 0.065 0.080 275.2 0.079 0.084 0.0041
8 0.022 0.034 194.4 0.027 0.037 0.0101
24 0.007 0.027 186.2 0.009 0.009 0.0004
Pigmented DA rat 3
37 0.25 0.049 0.050 213.9 0.132
0.50 0.076 0.078 274.0 0.205
0.75 0.078 0.081 272.9 0.211
4 0.033 0.041 167.0 0.089
8 0.017 0.027 212.4 0.047
24 0.004 0.013 177.7 0.010
